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Blue you sit so pretty west of the one
sparkles light with yellow icing, just a mirror for the sun.
Anthony Kiedis et al.
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Abstract
Primary testicular lymphoma (PTL) is a rare lymphoma entity presenting in an immune-privi-
leged site of the testis. The most common histology is activated B-cell-like (ABC) or non-ger-
minal center B-cell-like (non-GCB) phenotype diffuse large B-cell lymphoma (DLBCL), often 
occurring with an aggressive clinical behavior and a relatively high relapse rate. Due to the 
rareness of the disease, no randomized clinical trials have been conducted in testicular DLBCL 
(T-DLBCL), and the currently recognized standard of care is based on retrospective analysis 
and few phase II trials.
During the last years, tumor microenvironment (TME) and tumor-related immunity have been 
the focus of many tumor biology studies, and the emergence of targeted therapies and check-
point	inhibitors	has	significantly	modulated	the	field	of	cancer	therapies.	The	role	of	distinct	
tumor-infiltrating	immune	cell	subtypes	and	their	immunophenotypes	has	not,	however,	been	
thoroughly studied in T-DLBCL.
The	aims	of	this	study	were	to	evaluate	the	efficacy	of	different	treatment	modalities	among	
T-DLBCL	patients	identified	from	the	pathology	databases	of	three	university	hospitals	in	Fin-
land	and	the	Danish	lymphoma	registry	as	well	as	to	characterize	tumor-infiltrating	immune	
cell	subtypes,	their	phenotypes	and	distribution	in	the	TME,	and	to	associate	the	findings	with	
known clinical and biological risk factors and survival of patients with T-DLBCL.
The	efficacy	of	different	treatment	modalities	was	evaluated	by	comparing	the	patient	out-
comes of altogether 189 Finnish and Danish T-DLBCL patients. Among these patients, intrave-
nously (IV) administered central nervous system (CNS) -targeted chemotherapy and treatment 
of	the	contralateral	testis	translated	into	significantly	longer	patient	survival,	especially	among	
elderly patients. Intrathecally (IT) administered CNS prophylaxis had no effect on the patient 
outcome,	and	rituximab	seemed	to	be	beneficial	among	high-risk	 (International	Prognostic	
Index (IPI) score 3-5) T-DLBCL patients. In our patient material, the overall CNS relapse rate 
was low, and no differences in the risk of CNS relapse could be observed between patients 
treated with different treatment modalities. However, the use of IV CNS-targeted chemother-
apy	significantly	improved	the	systemic	control	of	lymphoma.
Tumor-infiltrating	immune	cell	subtypes,	their	phenotypes	and	distribution	in	the	TME	were	
studied using gene expression analysis and multiplex immunohistochemistry (mIHC) on tissue 
microarray (TMA) slides of 60–79 Finnish T-DLBCL patients. We observed that higher expres-
sion of 121 T-lymphocyte signature genes enriched for T-lymphocyte markers associated with 
significantly	longer	survival	of	T-DLBCL	patients.	The	association	with	survival	was	especially	
evident among rituximab-treated T-DLBCL patients and could also be seen in an independent 
cohort of 96 primary DLBCL patients.
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Altogether,	we	observed	a	great	variation	in	the	distribution	of	distinct	tumor-infiltrating	lym-
phocyte (TIL) phenotypes. Higher proportions of CD3+ TILs in general, CD4+ TILs, and CD8+ 
cytotoxic T-lymphocytes (CTLs) translated into better outcome. Higher proportions of pro-
grammed cell death-1 (PD-1) expressing CD4+	 TILs	 and	CTLs	 associated	with	 significantly	
longer patient survival. Despite the overall favorable prognostic impact of high TIL content, a 
subpopulation of FoxP3+T-bet+ double-positive regulatory T-cells (Tregs)	could	be	identified	to	
have	a	significant	adverse	effect	on	the	patient	outcome.
We were able to show that a large proportion of both tumor-associated macrophages (TAMs) 
and lymphoma cells expressed programmed cell death ligand 1 (PD-L1), and higher propor-
tions of PD-L1+CD68+ TAMs associated with longer survival. The content of PD-L1+CD68+ 
TAMs correlated with the content of PD-1+CD4+ TILs and PD-1+ CTLs, and the proportion of 
PD-L1+CD68- cells did not have an effect on the outcome of T-DLBCL patients.
In conclusion, our results support the use of the currently recognized standard of care with 
anthracycline-based immunochemotherapy and IV CNS-targeted chemotherapy with prophy-
lactic	treatment	of	the	contralateral	testis	as	the	first-line	treatment	of	patients	with	T-DLBCL.	
The	results	from	our	biological	studies	provide	novel	information	on	tumor-infiltrating	immune	
cell subtypes and their phenotypes, their association with known clinical and biological risk 
factors as well as survival among patients with T-DLBCL. Future studies should focus on fur-
ther	characterizing	the	functional	role	of	distinct	tumor-infiltrating	immune	cells	as	well	as	on	
evaluating new, less toxic, targeted therapies in T-DLBCL also for elderly, more fragile patients.
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Tiivistelmä suomeksi
Primaari kiveslymfooma on harvinainen ja kliiniseltä käyttäytymiseltään aggressiivinen lymfoo-
ma-alatyyppi, johon liittyy korkea taudin uusiutumisriski. Se esiintyy veri-kivesesteen suojaa-
massa kiveksessä ja edustaa histologialtaan yleisimmin aktivoituneen B-solun kaltaisen (ABC) 
tai ei-itukeskussoluperäisen (non-GCB) fenotyypin diffuusia suurisoluista B-solulymfoomaa. 
Taudin harvinaisuudesta johtuen primaarin kiveslymfooman hoidoista ei ole tehty satunnais-
tettuja kliinisiä hoitotutkimuksia, vaan yleisesti hyväksytty standardihoito perustuu takautuviin 
tutkimuksiin ja muutamaan faasin II tutkimukseen.
Viime vuosien aikana kasvainten mikroympäristö ja kasvaimiin liittyvä immuniteetti ovat olleet 
monien biologisten tutkimusten kohteena. Uusien kohdennettujen hoitojen ja immuuni vasteen 
tarkistuspisteeseen vaikuttavien vasta-aineiden myötä syöpähoitojen kirjo onkin oleellisesti 
muuttunut. Kasvaimeen liittyvien immuunisolujen alaryhmien osuuksia ja kliinistä merkitystä 
primaarissa kiveslymfoomassa ei kuitenkaan ole aiemmin perusteellisesti tutkittu.
Tutkimuksen tavoitteina oli arvioida eri hoitomuotojen tehoa primaarin kiveslymfooman hoi-
dossa ja selvittää kasvaimeen liittyvien immuunisolujen alaryhmien immuunifenotyyppejä 
ja jakautumista, sekä verrata tuloksia tunnettuihin kliinisiin ja biologisiin primaarin kives-
lymfooman ennustetekijöihin sekä potilaiden hoitovasteeseen ja elossaoloon.
Eri hoitomuotojen tehoa arvioitiin vertailemalla 189 primaaria kiveksen diffuusia suurisoluista 
B-solulymfoomaa sairastaneen potilaan elossaolotietoja, jotka kerättiin kolmen suomalaisen 
yliopistosairaalan patologian tietokannoista sekä Tanskan lymfooma rekisteristä. Näiden poti-
laiden keskuudessa suonensisäinen keskushermostoon kohdennettu ja vastakkaisen kiveksen 
suojaava hoito paransivat merkittävästi potilaiden ennustetta, erityisesti iäkkäämpien potilai-
den keskuudessa. Aivoselkäydinnesteeseen annettu keskushermostoon kohdennettu hoito 
ei vaikuttanut potilaiden ennusteeseen. Rituksimabi vaikutti hyödyttävän erityisesti korkean 
uusiutumisriskin (International  Prognostic Index (IPI) pisteet 3–5) potilaita. Keskushermostouu-
siutumien määrä oli aineistossamme kaiken kaikkiaan pieni, eikä eri hoitomuodoilla hoidettu-
jen potilaiden välillä havaittu eroja keskushermostouusiutumien määrän suhteen. Suonensisäi-
nen keskushermostoon kohdennettu hoito paransi kuitenkin merkittävästi lymfoomapotilaiden 
kokonaiselinaikaa.
Kasvaimeen liittyvien immuunisolujen alaryhmien immuunifenotyyppejä ja jakautumista tut-
kittiin käyttäen geeniekspressioanalyysiä ja multiplex-immunohistokemiaa (mIHK) hyödyntäen 
60–79 suomalaisen kiveksen diffuusia suurisoluista B-solulymfoomaa sairastaneen potilaan 
kasvainkudoksen mikrosirunäytteitä. Havaitsimme korkean 121 T-lymfosyyttimerkkiaineiden 
suhteen rikastuneen geenijoukon ilmentymistason olevan selkeästi yhteydessä potilaiden 
pidempään elossaoloaikaan. Yhteys ennusteeseen oli havaittavissa erityisesti immunokemoter-
apiahoidetuilla potilailla, ja nähtävissä myös itsenäisessä 96 primaaria diffuusia suurisoluista 
B-solulymfoomaa sairastaneen potilaan aineistossa.
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Havaitsimme kaiken kaikkiaan suurta vaihtelua kasvaimeen liittyvien T-solujen alatyypeissä eri 
potilaiden välillä. Yleisesti korkeampi CD3+-kasvaimeen liittyvien T-solujen määrä sekä kor-
keampi CD4+-T-solujen ja CD8+-sytotoksisten T-solujen määrä johti potilaiden parempaan 
selviytymiseen. Myös korkeampi programmed cell death-1 (PD-1) -molekyyliä ilmentävien 
kasvaimeen liittyvien CD4+-T-solujen sekä CD8+-sytotoksisten T-solujen osuus oli yhteydessä 
potilaiden pidempään elossaoloon. Huolimatta yleisestä kasvaimeen liittyvien T-solujen kor-
keampaan määrään yhteydessä olevasta paremmasta ennusteesta löysimme FoxP3+T-bet+ 
kaksoispositiivisten säätelevien T-solujen alaryhmän, joka oli yhteydessä potilaiden merkitse-
västi huonompaan selviytymiseen.
Pystyimme osoittamaan, että suuri osuus sekä kasvaimeen liittyvistä makrofaageista että 
lymfoomasoluista ilmentää ohjelmoidun solukuoleman ligandia 1 (PD-L1), ja korkeampi 
PD-L1+CD68+-kasvaimeen liittyvien makrofaagien määrä on yhteydessä potilaiden pidempään 
elossaoloon. PD-L1+CD68+-kasvaimeen liittyvien makrofaagien määrä korreloi PD-1+CD4+-kas-
vaimeen liittyvien T-solujen ja PD-1+-sytotoksisten T-lymfosyyttien määrään, eikä PD-L1+CD68– 
-solujen osuudella ollut vaikutusta potilaiden selviytymiseen.
Yhteenvetona voidaan todeta, että tuloksemme puoltavat nykyisen antrasykliinipitoisen 
immuno kemoterapian ja suonensisäisen keskushermostoon kohdennetun sekä vastakkaisen 
kiveksen suojaavan hoidon käyttöä kiveksen diffuusia suurisoluista B-solulymfoomaa sairas-
tavien potilaiden ensilinjan hoitona. Biologisten tutkimustemme tulokset tuovat uutta tietoa 
kasvaimeen liittyvistä immuunisoluista, niiden alaryhmistä sekä niiden yhteyksistä tunnettuihin 
kliinisiin ja biologisiin ennustetekijöihin ja kiveksen diffuusia suurisoluista B-solulymfoomaa 
sairastavien potilaiden elossaoloon. Tulevien tutkimusten tulisi keskittyä selvittämään eri kas-
vaimeen liittyvien immuunisolujen toimintaa sekä arvioimaan uusia, aiempaa paremmin sie-
dettyjä, kohdennettuja hoitoja kiveksen diffuusissa suurisoluisessa B-solulymfoomassa, myös 
vanhempien ja hauraampien potilaiden kohdalla.
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1 Introduction
Lymphoma is a malignancy of the lymphocytes or the natural killer (NK) cells that can arise 
in the lymphoid organs such as lymph nodes and the spleen, or extranodal sites such as the 
bone	marrow,	the	central	nervous	system	(CNS)	or	testis.	Lymphomas	were	first	discovered	
by Thomas Hodgkin who studied enlarged lymph nodes and spleens of children and young 
adults in the 19th century [1]. The malignant Hodgkin lymphoma (HL) cells were recognized 
about 60 years later, and were later named Hodgkin-Reed-Sternberg (HRS) cells after Thomas 
Hodgkin, Dorothy Reed, and Carl Sternberg [2]. Since then, over 70 distinct lymphoma entities 
have been recognized, with the incidence ranging between 48–60/100,000/year in Finland 
during	the	last	few	decades	(https://syoparekisteri.fi).	
Lymphomas	were	first	classified	according	to	their	morphology	after	the	Rappaport	classi-
fication	[3].	With	the	constantly	increasing	information	on	lymphoma	biology,	the	classification	
of lymphoid malignancies were thereafter revised by Kiel and Real before the introduction of 
the	WHO	lymphoma	classifications,	which	have	also	been	renewed	and	revised	several	times	
[4-6] To put it simply, lymphomas used to be divided into HLs and non-Hodgkin lymphomas 
(NHLs). This division, however, tells perhaps more about the history than the biology of the 
diseases, since some HLs are nowadays known to share features with other B-cell lymphom 
as [6]. Lymphomas can, nevertheless, be divided into HLs, B-cell lymphomas, and T-/NK cell 
lymphomas, according to the nature of the malignant cells, although the current WHO Classi-
fication	of	Tumours	of	Haematopoietic	and	Lymphoid	Tissues,	Revised	4th	Edition	no	longer	
recognizes	the	definition	of	NHL	[6].	B-cell	lymphomas	are	much	more	common	than	T-/NK	
cell	 lymphomas,	 as	only	 10–15%	of	 all	 lymphomas	previously	 classified	as	NHLs	 represent	
peripheral T-cell lymphomas [7]. B-cell lymphomas as well as T-cell lymphomas can be divided 
according to their clinical behavior into aggressive and indolent diseases. Aggressive lym-
phomas are considered potentially curable diseases, whereas indolent lymphomas can have a 
very peaceful clinical behavior, with even spontaneous regression, and can therefore often be 
considered for a watch-and-wait policy instead of immediate oncological treatments.
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell malignancy 
covering	30–58%	of	all	lymphomas	previously	classified	as	NHLs,	with	a	significantly	rising	inci-
dence from 0.75/100,000/year to 12/100,000/year in Finland during the 21st century (https://
cancerregistry.fi)	[8].	DLBCL,	not	otherwise	specified	(NOS)	constitutes	25–35%	of	adult	NHLs	in	
developing countries, is more common in elderly individuals, and slightly more common in males 
[6]. Depending on the clinical and biological risk factors, 50–90% of DLBCL patients can be cured 
with standard treatment options. Extranodal presentation is a known clinical risk factor in DLBCL. 
Primary testicular lymphoma (PTL) is a rare and aggressive extranodal lymphoma arising primarily 
in the immune-privileged site of the testis and most commonly representing DLBCL histologically 
[9].	It	accounts	for	about	1–2%	of	all	lymphomas	previously	classified	as	NHLs	and	for	about	5%	of	
all testicular malignancies, yet being the most common testicular neoplasm in elderly men [9-14].
Due to the rareness of testicular DLBCL (T-DLBCL), no randomized phase III trials have 
been conducted and the internationally recognized standard of care is based on data from 
phase II trials [15,16]. The median 5-year overall survival (OS) and progression-free survival 
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(PFS) rates with standard treatment have been reported to be around 85% and 75%, respec-
tively [15]. T-DLBCL has a high tendency of relapsing in other extranodal sites, most commonly 
the contralateral testis and the CNS, and especially relapses in the CNS have been associated 
with poor prognosis [17]. Treatment approaches have therefore been targeted with the aim of 
gaining both local and systemic effectiveness as well as prevention of a possible CNS relapse.
The tumor microenvironment (TME) consists of different host immune cells, stromal cells, 
blood vessels, cell matrix, and numerous cytokines, chemokines, and exosomes [18]. The role 
of host immunity in tumor evolution and tumor growth inhibition was already recognized sev-
eral decades ago. However, only the recent increasing understanding of the complexity of the 
host-related	factors	and	immune	escape	has	led	to	major	advancements	in	the	medical	field,	
as checkpoint inhibitors and other immune modulators have been shown to be effective in 
several malignancies including lymphomas [18-21].
The studies in this thesis were planned and conducted with the aim of gaining novel 
information	 on	 the	 TME	 of	 T-DLBCL.	 The	 role	 of	 tumor-infiltrating	 lymphocytes	 (TILs)	 and	
tumor-associated macrophages (TAMs) and the expression of checkpoint molecules as well 
as T-cell exhaustion in T-DLBCL had not been thoroughly studied before and were the main 
focus of this thesis. Additionally, this thesis provides important information on the treatment 
outcomes of a large retrospectively analyzed Nordic T-DLBCL series, increasingly important in 
the lack of randomized phase III trials in this rare and unique lymphoma entity.
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2 Review of the literature
2.1 B-cell differentiation and lymphoma pathogenesis
Naïve B-cells are produced by the bone marrow and differentiate into memory B-cells and 
antibody (Ab)-producing plasma cells essential for long-lived humoral immunity [22]. The 
migration, activation, differentiation, and proliferation of B-cells is regulated by several differ-
ent mechanisms including antigens and pathogens, other immune cells, as well as different 
cytokines and chemokines. In this chapter, the main principles of B-cell evolution are reviewed, 
leaving out a more thorough description of all the mechanisms involved.
Naïve lymphocytes home from bone marrow to lymph nodes and spleen in high endothe-
lial venules [23,24]. To be activated in the lymph nodes, B-cells need to encounter antigens 
either presented to B-cells by antigen-presenting cells (APCs), mainly macrophages and den-
dritic cells (DCs), or in soluble form; both in the B-cell follicles of the lymph node cortex [25]. 
The antigens are bound by B-cell receptors (BCRs), internalized, and again presented by the 
B-cells via major histocompatibility complex (MHC) class II to further induce T-cell activation 
as well as B-cell differentiation and proliferation [26]. The differentiation of activated B-cells 
into memory B-cells can be either germinal center (GC)-derived or GC-independent whereas 
differentiation into plasma cells mainly occurs in GCs [22,27,28].
GC-derived	differentiation	is	conducted	in	the	GC	of	the	B-cell	follicle	where	B-cells	first	
proliferate in the ‘dark zone’, then differentiate in the ‘light zone’, and again re-enter the ‘dark 
zone’	for	further	rounds	of	proliferation	and	somatic	hypermutation	(SHM),	BCR-affinity-based	
selection, or apoptosis [29-31]. Antibodies produced by mature B-cells are coded by immuno-
globulin heavy chain variable region (IgVH) genes, and SHM of the IgVH genes in combination 
with	affinity-based	 selection	 is	essential	 for	 the	development	of	high-affinity	Ab-producing	
B-cells [29,31-34]. The GC-independent differentiation occurs outside the GC in a pre-GC 
phase regulated by T follicular helper (Tfh) cells, also involved in initiating the differentiation of 
some B-cells into plasma cells [27,28,33]. Additionally, interactions between B-cells and T-cells 
are essential for proper B-cell function and Ab production. T-cell help is required for gaining 
entry of B-cells into the GC pathway of memory B-cell differentiation as well as for later mem-
ory B-cell proliferation and differentiation into plasma cells following antigen recall [26,27,35].
Many B-cell lymphomas show similarities to normal B-cell developmental stages accord-
ing	to	their	immunophenotype,	histological	appearance,	and	gene	expression	profile.	In	lym-
phomas, however, the normal signaling pathways can be altered, leading to constitutively 
activated pro-survival pathways [36]. Increasing knowledge on genetic alterations as well as 
modifications	in	the	intracellular	pathways	and	the	TME	has	consistently	led	to	better	under-
standing of lymphoma pathogenesis [36-39].
Some	B-cell	 lymphoma	entities	can	be	associated	with	a	specific	B-cell	developmental	
stage: the majority of Burkitt lymphomas (BLs), follicular lymphomas (FLs), and germinal center 
B-cell-like	(GCB)	DLBCLs	have	gene	expression	profiles	most	similar	to	B-cells	of	the	GC	‘light	
zone’, although some BLs seem to be more close to cells from the ‘dark zone’ [39-41]; acti-
vated B-cell-like (ABC) DLBCL cells have experienced the GC phase and are closest to plas-
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mablast stage of B-cell development [36,39,40]; mantle cell lymphoma (MCL) cells resemble 
naïve B-cells but a minority of them show SHM, indicating that they have undergone the GC 
phase [42]; and mucosa-associated lymphoid tissue (MALT) lymphoma cells resemble post-GC 
B-cells of the outer layer of B-cell follicle named the marginal zone [43]. A summary of B-cell 
development and the origin of malignant cells in distinct lymphoma entities is shown in Figure 
1. The cell-of-origin (COO) in DLBCL and T-DLBCL is reviewed more closely in section 2.3.1.
Figure 1. B-cell development and the origin of malignant cells in distinct lymphoma 
entities. In the normal GC-derived differentiation, B-cells proliferate in the ‘dark zone’ of 
the GC and differentiate in the ‘light zone’, and again re-enter the ‘dark zone’ for further 
rounds	 of	 proliferation	 and	 SHM,	 BCR-affinity-based	 selection,	 or	 apoptosis.	 Some	 B-cell	
lymphoma	entities	can	be	associated	with	a	specific	B-cell	developmental	stage	according	to	
their	immunophenotype,	histological	appearance,	and	gene	expression	profile.	The	majority	
of	BLs,	FLs,	and	GCB	phenotype	DLBCLs	have	gene	expression	profiles	most	similar	to	B-cells	
of the GC ‘light zone’; ABC phenotype DLBCL cells have experienced the GC phase and are 
closest to plasmablast stage of B-cell development, whereas MCL cells resemble naïve B-cells 
and MALT lymphoma cells resemble post-GC B-cells of the outer layer of the B-cell follicle 
named the marginal zone. Adjusted from Pasanen et al. 2017 [44].
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The most important signaling pathways in lymphoma pathogenesis include nuclear factor 
kappaB (NF-κB), BCR, and Toll-like receptor (TLR) signaling pathways [36]. Activation of NF-κB 
pathway promotes cell survival by several distinct mechanisms as well as antagonizes apoptotic 
action of chemotherapy and is considered a hallmark of ABC-DLBCL (discussed more closely in 
section 2.3.1) [36,45,46]. The activation of NF-κB signaling pathway can be induced by a multido-
main signaling adapter caspase recruitment domain family member 11 (CARD11) or alternatively, 
by Bruton’s tyrosine kinase (BTK), a tyrosine kinase functioning downstream of BCR [36,47-49]. 
Furthermore, CARD11 functions through regulating downstream factors such as mucosa-associ-
ated lymphoid tissue lymphoma translocation gene 1 (MALT1) protein product MALT1, another 
significant	 growth-promoting	 protein	 that	 potentiates	 NF-κB signaling by activating further 
downstream factors and by inactivating negative regulators of the signaling pathway [50-54].
As previously described, BCR is essential in B-cell development, antigen-driven clonal 
selection, and humoral immunity. It consists of signal transducing immunoglobulin (Ig) α 
(CD79A) and Igβ (CD79B) subunits that regulate BCR surface expression, internalization, and 
trafficking,	while	antigen	specificity	of	BCR	is	provided	by	the	surface	Ig	[55,56].	After	BCR	
clustering and antigen encounter, the subunits transmit signals to several downstream signal-
ing pathways including the NF-κB pathway [56,57].
TLR activation has a role in normal peripheral B-cell responses and autoimmune humoral 
responses [55,58-60]. TLRs regulate various downstream signaling pathways, including the 
NF-κB pathway [61,62]. In lymphoma pathogenesis, upregulation of TLR signaling pathway 
is mainly mediated by adapter protein MYD88, MYD88 mutations being oncogenic gain-of-
function mutations [63]. MYD88 is known to be essential in ABC-DLBCL as knockdown of 
MYD88 has been shown to be toxic in ABC-DLBCL cell lines [63]. Additionally, BCR signaling 
and MYD88/TLR-mediated signaling have been demonstrated to collaborate in a synergic 
manner in autoimmune diseases and have also been suggested to have synergistic function in 
lymphoma pathogenesis [36,60,63].
Further	modifications	in	distinct	intracellular	signaling	pathway	mechanisms	are	beyond	
the scope of this thesis and are therefore not discussed more thoroughly in this literature 
review. The role of TME is reviewed in section 2.4.
2.2 Lymphoma classification
Lymphoma	entities	are	classified	according	to	the	World	Health	Organization	(WHO)	classifi-
cation of Tumours of Haematopoietic and Lymphoid Tissues. The latest version of the WHO 
classification	is	the	Revised	Fourth	Edition	published	in	2017	[6].	The	classification	defines	the	
diagnostic criteria and genetic/molecular landscape of lymphoma entities as well as reviews 
the	latest	most	important	advancements	in	the	field	of	lymphoma	biology	research,	discuss-
ing	also	the	therapeutic	approaches	in	lymphoid	neoplasms.	The	classification	is	a	consensus	
among hematopathologists, geneticists, and clinicians, and describes over 90 different enti-
ties of which aggressive mature B-cell lymphomas are listed in Table 1, according to the latest 
revised Fourth Edition [6].
DLBCL is the most common lymphoma entity and the most common histology of PTL. All 
PTL patients in this thesis represent T-DLBCL and the subsequent literature review is therefore 
focused on DLBCL in general and T-DLBCL.
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Table 1. Aggressive mature B-cell neoplasms according to WHO classification of Tumours 
of Haematopoietic and Lymphoid Tissues, the revised Fourth Edition.
Diffuse large B-cell lymphoma (DLBCL), NOS
  Germinal center B-cell subtype
  Activated B-cell subtype
T-cell/histiocyte-rich large B-cell lymphoma
Primary DLBCL of the CNS
Primary cutaneous DLBCL, leg type
EBV+ DLBCL, NOS
EBV+ mucocutaneous ulcer
DLBCL	associated	with	chronic	inflammation
  Fibrin-associated diffuse large B-cell lymphoma
Primary mediastinal (thymic) large B-cell lymphoma
Intravascular large B-cell lymphoma
ALK+ large B-cell lymphoma
Plasmablastic lymphoma
Primary effusion lymphoma
HHV8+ DLBCL, NOS
Burkitt lymphoma
Burkitt-like lymphoma with 11q aberration
High-grade B-cell lymphoma
  High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements
  High-grade B-cell lymphoma, NOS
B-cell	lymphoma,	unclassifiable,	with	features	intermediate	between	DLBCL	and	
classic Hodgkin lymphoma
Provisional entities listed in italics. EBV, Epstein-Barr virus; ALK, Anaplastic Lymphoma Kinase; HHV8, Human herpesvirus 8. 
Adjusted from Swerdlow et al. 2017 [6].
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2.2.1 Diffuse large B-cell lymphoma (DLBCL)
By	definition,	DLBCL	 is	a	neoplasm	of	 large	B	 lymphoid	cells	with	nuclear	size	equal	 to	or	
exceeding normal macrophage nuclei or more than twice the size of a normal lymphocyte, 
that has a diffuse growth pattern [6]. The neoplastic cells typically express pan-B-cell markers 
such as CD19, CD20, CD22, CD79a, and PAX5, but may also lack one or more of these [6]. 
Surface and cytoplasmic Ig, most commonly IgM, can be demonstrated in 50–75% of the 
cases and the neoplastic cells express CD5 in 5–10% of the cases [6]. Proliferation index Ki-67 
is high, usually varying between 40% and >90% [6]. Expression of p53 occurs in 20–60% of 
the cases, being more common than mutations of TP53, further suggesting a possible upreg-
ulation of wildtype TP53 in some cases [6]. Expression of c-Myc, Bcl-2, and Bcl-6 varies and is 
discussed in more detail later in sections 2.3.1 and 2.3.2.
The	WHO	classification	of	Tumours	of	Haematopoietic	and	Lymphoid	Tissues,	the	revised	
Fourth Edition, subdivides DLBCL into morphological variants, molecular subtypes and dis-
tinct disease entities according to morphological, biological, and clinical studies [6]. Additional 
entities with features intermediate between DLBCL and BL (High-grade B-cell lymphoma, with 
MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements; and 
high-grade B-cell lymphoma, NOS) or DLBCL and classical HL (cHL) (B-cell lymphoma, unclas-
sifiable,	with	features	intermediate	between	DLBCL	and	classical	Hodgkin	lymphoma)	are	rec-
ognized, Table 1 [6].
DLBCL,	NOS	 comprises	 all	 DLBCL	 cases	 that	 do	 not	 follow	 any	 of	 the	 listed	 specific	
DLBCL diagnostic categories, Table 1 [6]. It can be further divided according to the COO clas-
sification	dividing	DLBCLs	into	GCB	and	ABC/non-GCB	phenotypes	[6].	The	COO	separates	
two entities with different chromosomal alterations, activation of signaling pathways, and clin-
ical outcome, and is addressed in more detail in section 2.3.1. [6,39,64,65].
High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements, the 
so-called ‘double-hit’ or ‘triple-hit’ lymphoma, is a highly aggressive lymphoma entity dis-
cussed in more detail later in section 2.3.2 focusing on Bcl-2, Bcl-6 and c-Myc. Other DLBCL 
entities	mentioned	in	the	WHO	classification	are	significantly	more	uncommon	and	only	very	
rarely presented in the testis, and are therefore not further discussed in this review.
2.2.2 Primary testicular diffuse large B-cell lymphoma (T-DLBCL)
The majority of PTL cases (75–90%) represent DLBCL, most commonly ABC/non-GCB phe-
notype,	 as	 described	 in	more	 detail	 in	 section	 2.3.1.	 [9,66-71].	 The	WHO	 classification	 of	
Tumours of Haematopoietic and Lymphoid Tissues, the revised Fourth Edition, does not yet 
recognize T-DLBCL as its own distinct entity, though increasing evidence shows marked dif-
ferences in the biology of DLBCL of the testis, many of them similar to primary DLBCL of the 
CNS (primary central nervous system lymphoma, PCNSL) [72-74], another DLBCL entity arising 
in	an	immune-privileged	site	and	recognized	as	its	own	entity	in	the	WHO	classification	[6].
Other lymphoma entities with reported testicular involvement are FL, MCL, immunoblas-
tic NHL, diffuse mixed cell NHL, T-cell lymphoma, BL, T-/NK cell lymphoma, and plasmacy-
toma [70,75-80]. Since all the patients studied in this thesis represented T-DLBCL, these other 
rare PTL subtypes are not further discussed in this literature review.
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2.2.2.1 Epidemiology and etiology
T-DLBCL is a rare lymphoma entity with reported annual incidence of 0.09–0.26 per 100,000 
population	[9-14].	It	accounts	for	about	1–2%	of	all	lymphomas	previously	classified	as	NHLs	
and about 5% of all testicular malignancies [9-14]. However, it is the most common testicular 
neoplasm in elderly men, with the previously reported median age at diagnosis varying from 
59 to 68 years [17,66,67,81-83]. In non-immune competent individuals, such as patients with 
HIV/AIDS, T-DLBCL may also arise in younger patients [84]. Additionally, T-DLBCL has been 
reported as the most common bilateral testicular malignancy with either concurrent or subse-
quent bilateral testicular involvement [10,12,83,85,86].
Little is known about the etiology of T-DLBCL, although HIV infection is a recognized risk 
factor for aggressive lymphomas and primary extranodal lymphomas [84,87]. Testis is, how-
ever, an immune-privileged site with several different mechanisms designed to protect the 
developing gametocytes [9,88-90]. This may serve T-DLBCL a distinct milieu ideal for develop-
ing an immune escape phenotype similar to PCNSL, another entity arising in an immune-priv-
ileged site, as T-DLBCL and PCNSL are known to share common genetic features such as high 
levels of IgVH gene SHM and common loss of human leukocyte antigen (HLA) gene expres-
sion, discussed in more detail in section 2.3.3 [74,91-94].
2.2.2.2 Symptoms, diagnosis, and staging
Most	commonly	T-DLBCL	presents	with	a	firm,	painless	mass	in	a	testis.	The	median	tumor	size	
at presentation is reported to be 4–6 cm with no preference for either side [13,69,95]. T-DL-
BCL is the most common bilateral testicular malignancy with either concurrent or subsequent 
involvement of the contralateral testis; synchronous bilateral involvement being described 
in 6–15% of the cases [11,13,67,69,83,86]. B-symptoms (fever, loss of weight, sweating) are 
rare and indicate a disseminated disease, present in 20–30% of the patients at diagnosis 
[17,67,69,83,96].
T-DLBCL has a high relapse rate and the recurrence often occurs in the contralateral 
testis or, most commonly, in the CNS [17,66,69,81,85]. Especially the involvement/recurrence 
of the CNS has been associated with a worse prognosis, and relapses in the CNS have been 
reported in up to 30% of the cases within 1–2 years from diagnosis [17,97]. Other reported 
extranodal sites of relapse are skin, subcutaneous tissue, lung, and Waldeyer ring, and late 
relapses even up to 10 years after primary diagnosis have been described [17,67,81,85,98].
The histopathological diagnosis of T-DLBCL is obtained from a tissue sample of the 
involved	testis,	according	to	the	latest	WHO	classification	of	Tumours	of	Haematopoietic	and	
Lymphoid Tissues [6]. Ultrasound of the contralateral testis and a contrast-enhanced computer 
tomography (CT) of the whole body and neck as well as bone marrow biopsy are required 
for	staging	[97].	Additional	18-fluorodeoxyglucose	positron	emission	tomography-computed	
tomography (18-FDG-PET-CT) is highly recommended as it is more sensitive in detecting pos-
sible other extranodal lymphoma lesions [99]. Magnetic resonance imaging (MRI) of the brain 
and	cytological	and	flow	cytometric	analysis	of	the	cerebrospinal	fluid	are	also	recommended	
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as part of lymphoma staging, although they are often carried out only if indicated by clinical 
symptoms	or	findings,	as	are	further	targeted	examinations	such	as	consultation	of	an	oph-
thalmologist [97].
The	stage	of	T-DLBCL	is	commonly	classified	by	the	Ann	Arbor	lymphoma	staging,	Table	
2 [96,97].
Table 2. Ann Arbor lymphoma stage classification. 
Stage Description
I Involvement of a single lymphatic region (I) or localized involvement of single 
extranodal organ or site (IE)
II Involvement of two or more lymphatic regions on the same side of the diaphragm 
(II) or localized involvement of a single extranodal organ or site and one or more 
lymphatic regions on the same side of the diaphragm (IIE)
III Involvement of lymphatic regions on both sides of the diaphragm
IV Diffuse or disseminated involvement of one or more extranodal organs with or 
without lymphatic involvement
Adjusted from Carbone et al. 1971 [96].
2.2.2.3 Clinical prognostic factors
Some clinical features such as higher age at diagnosis and advanced stage disease (stage 
III-IV) are known to associate with worse prognosis in patients with DLBCL [100]. The same 
clinical prognostic factors have been shown to predict the outcome of T-DLBCL patients [66-
69,71,82,83,85,101-103].	Based	on	these	findings,	the	prognosis	of	patients	with	DLBCL	and	
T-DLBCL can be estimated according to the International Prognostic Index (IPI) or the modi-
fied	age-adjusted	IPI	(aaIPI),	Tables	3	and	4,	respectively	[8,100,104].	
Table 3. International Prognostic Index. 
Risk group IPI score 3-year OS, (95% CI), %
Low 0 or 1 91 (89–94)
Intermediate low 2 81 (76–86)
Intermediate high 3 65 (58–73)
High 4 or 5 59 (49–69)
1 score for each: Stage III-IV, elevated Lactate Dehydrogenase, age over 60 years at diagnosis, ECOG performance status 3-4, 
more than 1 extranodal lymphoma site. Adjusted from Ziepert et al. 2010 [104].
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Table 4. Age-adjusted International Prognostic Index.
Risk group aaIPI score 3-year OS, (95% CI), %
Low 0 98 (96–100)
Intermediate low 1 92 (87–95)
Intermediate high 2
75 (66–82)High 3
1 score for each: Stage III-IV, elevated Lactate Dehydrogenase, ECOG performance status 3-4. Adjusted from Tilly et al. 2015 [8].
Since	the	original	IPI	was	determined	in	the	pre-rituximab	era,	modifications	of	IPI	have	
been launched for patients treated with immunochemotherapy. The revised IPI (R-IPI) uses 
the same clinical prognostic factors as the original IPI to identify three distinct prognostic 
subgroups within immunochemotherapy-treated DLBCL patients and has been reported to 
predict the outcome of these patients better than the original IPI, Table 5 [105]. The National 
Comprehensive Cancer Network IPI (NCCN-IPI) similarly uses the clinical prognostic factors 
of the original IPI to divide immunochemotherapy-treated DLBCL patients into four different 
subgroups	with	discriminated	prognosis,	Table	6	[106].	Since	the	use	of	these	modified	prog-
nostic indexes has not been validated in larger trials, and the original IPI has been validated 
as prognostic also in the rituximab era, the decision-makingin in daily clinical practice is, none-
theless, still based on the original IPI [104].
Table 5. Revised International Prognostic Index. 
R-IPI Number of IPI factors 4-year PFS, % 4-year OS, %
Very good 0 94 94
Good 1, 2 80 79
Poor 3, 4, 5 53 55
IPI, International Prognostic Index; PFS, Progression-free survival; OS, Overall survival. Adjusted from Sehn et al. 2007 [105].
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Table 6. National Comprehensive Cancer Network International Prognostic Index. 
Factor Score NCCN-IPI Total Score 5-year 
PFS, %
5-year 
OS, %
Age, years Low 0, 1 91 96
	 	 >	40	to	≤60 1 Low-intermediate 2, 3 74 82
	 	 >60	to	≤75 2 High-intermediate 4, 5 51 64
  over 75 3 High ≥6 30 33
LDH-ratio
	 	 >1	to	≤3 1
  over 3 2
Ann Arbor stage III-IV 1
Extranodal disease 1
ECOG performance status ≥2 1
PFS, Progression-free survival; OS, Overall survival; LDH, Lactate Dehydrogenase. Adjusted from Zhou et al. 2014 [106].
2.2.2.4 Treatments
Besides reaching a complete remission, the intention of T-DLBCL treatment has been to pre-
vent relapses of the contralateral testis and the CNS [17]. Due to rareness of the disease, there 
are no randomized phase III trials and the internationally recognized standard of care mainly 
relies on two prospective phase II trials [15,16]. Based on these trials, the backbone of T-DLBCL 
treatment is considered to be orchiectomy followed by immunochemotherapy with six cycles 
of R-CHOP (rituximab-doxorubicin-cyclophosphamide-vincristine-prednisone) or R-CHOP-like 
regimen given every 21 days [97]. The addition of CNS prophylaxis with intravenously (IV) 
administered CNS-penetrating chemotherapy such as high dose methotrexate (HD-Mtx) or 
high dose cytarabine (HD-Ara-C) and/or intrathecal (IT) chemotherapy as well as irradiation or 
excision of the contralateral testis are recommended [15,16,85,97]. Supporting the data from 
phase II trials, the use of anthracycline-based chemotherapy has been shown to improve the 
outcome of T-DLBCL patients also in retrospective series [85]. Correspondingly and in line 
with	findings	on	DLBCL	in	general,	anti-CD20	monoclonal	antibody	(mAb)	rituximab	has	been	
reported	beneficial	 in	T-DLBCL	 in	 retrospective	analysis	 [16,102].	The	use	of	CNS-targeted	
chemotherapy is recommended although data on whether it should be administered IT or 
IV is scarce, and the risk of CNS relapse has not decreased in the rituximab era [102]. On the 
contrary, data on irradiation of the contralateral testis reducing the risk of recurrence of the 
contralateral testis is more convincing [15,16,101].
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2.3 Biology of DLBCL and T-DLBCL
2.3.1 Cell of origin (COO)
The	original	COO	classification,	a	study	based	on	gene	expression	profiling	(GEP)	of	3,186	
genes with known importance to lymphocyte and/or cancer biology, was published in 2000 
separating two distinct DLBCL entities with different clinical outcomes and different gene 
expression patterns, indicating separate stages of B-cell differentiation [39]. Tumors with GCB 
phenotype were shown to express genes characteristic of GC B-cells whereas tumors with ABC 
phenotype expressed genes that are normally induced during in vitro activation of peripheral 
blood	cells	[39].	Patients	with	GCB	phenotype	were	reported	to	have	significantly	longer	OS	
compared	to	patients	with	ABC	phenotype,	and	the	findings	have	later	been	confirmed	by	
other	studies,	although	trials	not	finding	an	association	with	COO	and	survival	have	also	been	
reported [39,40,107-109].
Since the original COO publication, an additional third molecular subgroup of primary 
mediastinal large B-cell lymphoma has been recognized, while a small proportion of all DLB-
CLs	still	 remains	unclassified	[6,110-112].	Furthermore,	 it	has	been	recognized	that	the	two	
original COO subgroups differ in their activation of signaling pathways such as the NF-κB 
pathway, commonly activated in ABC phenotype [36,45,47,64]. The mutation status of dis-
tinct oncogenes also varies, with e.g. CARD11, myeloid differentiation primary response gene 
88 (MYD88), and MALT1 all being more commonly mutated in ABC phenotype [49,63,113]. 
Some of the main differences between ABC and GCB phenotypes are summarized in Table 7.
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Table 7. Differences in disease characteristics between ABC and GCB DLBCL. 
Characteristics ABC DLBCL GCB DLBCL
Median age at diagnosis 66 years 61 years
Immunophenotype CD20+, IRF+, FoxP1+, 
CD10-, BCL6-, GCET1-, 
LMO2-
CD20+, CD10+, 
BCL6+, GCET+, 
LMO2+, IRF4-, FoxP1-
Frequency in 
ABC-DLBCL
Frequency in 
GCB-DLBCL
Rearrangements
BCL2 < 5% 40%
BCL6 25–30% 15%
MYC, single hit < 5–8% < 5–8%
CD274/PDCD1LG2 
(coding PD-L1 and PD-L2)
Rare Rare
Copy-number alterations
9p24.1	gains/amplifications	
(CD274/PDCD1LG2)
Uncommon Uncommon
18q21.3	gain/amplification	(BCL2) 55% 15%
Recurrent mutations
TP53 25% 20%
CARD11 10–15% 10–15%
CD79B 20-25% Uncommon
MYD88 35% Uncommon
Pathway perturbations
NF-κB activation Yes No
PI3K/AKT No Yes
JAK/STAT signaling Rare Yes
Clinical features
5-year PFS (R-CHOP) 40-50% 70-80%
Adjusted from Shaffer et al. 2012 and Swerdlow et al. 2017 [6,36].
As GEP is not yet available as routine clinical practice in most laboratories, more fea-
sible techniques such as immunohistochemistry (IHC) based algorithms have been studied 
in determining the COO [65,114-116]. The most commonly used IHC algorithm is the Hans 
algorithm	which	classifies	COO	into	GCB	or	non-GCB	phenotypes	based	on	the	expression	of	
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CD10,	Bcl-6,	and	MUM1,	with	significantly	worse	OS	reported	among	patients	with	non-GCB	
phenotype	[65].	The	classification	scheme	used	in	the	Hans	algorithm	is	described	in	Figure	
2.	All	IHC-based	COO	classifications	may,	however,	have	reproducibility	problems	between	
laboratories, and their reported prognostic value has been inconsistent [117,118]. They have 
also	been	 reported	not	 to	 recognize	 the	10–15%	of	 tumors	determined	as	unclassified	by	
GEP [6]. Compared to IHC-based algorithms, newer methods such as assays with RNA tran-
script	quantification	of	14–20	genes	have	shown	better	reproducibility	as	well	as	separation	of	
the	two	distinct	COO	prognostic	subgroups	corresponding	to	the	original	COO	classification	
[119-123].	As	they	have	not	been	validated	in	larger	trials,	the	IHC-based	classification	of	COO	
is still currently most commonly used in daily clinical practice, and the newer methods may 
serve	as	a	promising	alternative	for	COO	classification	in	the	future.
Figure 2. The Hans algorithm. The	IHC-based	Hans	algorithm	classifies	COO	into	GCB	or	
non-GCB phenotypes based on the expression of CD10, Bcl-6, and MUM1. 
Adjusted from Hans et al. 2004 [65].
The	majority	of	T-DLBCLs	represent	ABC/non-GCB	DLBCL,	defined	with	either	GEP-	or	
IHC-based algorithms, respectively, with the frequency varying between 60–96% accord-
ing to proportion of patients with advanced stage disease and the IHC algorithm used 
[9,69,70,73,103,124-127]. The Hans algorithm has been the most commonly used COO classi-
fication	in	T-DLBCL	studies	[65].	It	has	been	discussed	whether	IHC-based	algorithms	designed	
to classify nodal DLBCL can appropriately be applied to extranodal  entities and whether GEP-
based methods could more accurately classify COO in extranodal diseases [9,73,126]. Accord-
ing to the only GEP-based study in T-DLBCL, the proportion of ABC phenotype was reported 
to be 96% [126].
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2.3.2 Bcl-2, Bcl-6, and c-Myc
BCL2	is	an	oncogene	coding	Bcl-2,	a	member	of	the	Bcl-2	protein	family,	first	discovered	in	FL	
in association with chromosomal translocation t(14;18) [128]. The Bcl-2 protein family can be 
divided into three separate groups according to the protein’s structure and function: proteins 
that participate in inhibiting apoptosis, and two different groups with proteins that function as 
pro-apoptotic proteins but differ by structure [129]. Bcl-2 belongs to the anti-apoptotic group 
that regulates survival of cells by inhibiting the initiation of apoptosis [130-132]. It is known 
to be crucial for the pathogenesis of lymphoma and has been associated with multidrug-re-
sistance in lymphoid malignancies [133-135]. High levels of Bcl-2 protein expression (more 
common in ABC-DLBCL) have been associated with poor prognosis in aggressive lymphomas, 
including DLBCL, while most of the studies showed no association to survival with BCL2 rear-
rangements (more common in GCB phenotype DLBCL) [136-146]. The main functions of BCL2 
are summarized in Figure 3.
Overexpression of Bcl-2 was originally thought to result from translocation t(14;18) but 
later studies have described additional alternative mechanisms for the upregulation of the 
gene, and elevated gene expression and Bcl-2 protein levels have also been reported without 
(14;18) [128,147-150]. In T-DLBCL, nine patients with Bcl-2 positive B-cell NHL of the testis 
with no translocation t(14;18) were described in the 1990s [150]. Another study reported two 
Bcl-2 positive cases of primary cutaneous DLBCL, leg type, with testicular involvement at 
diagnosis, having identical clinicopathological and immunophenotypical features in their skin 
lesions as in the tumors of the testis, further interpreting both cases as T-DLBCL with cutane-
ous	involvement	[151].	In	a	larger	T-DLBCL	phenotype	profiling	study,	4%	of	the	studied	cases	
showed BCL2	rearrangements	and	15%	of	the	cases	an	amplification	of	BCL2, while Bcl-2 was 
reported to be expressed in 70% of the studied T-DLBCL cases [127].
BCL6 is a transcription factor suppressing c-Myc and Bcl-2 expression as well as NF-κB 
pathway activation [152-155]. It is essential in normal GC reaction and B-cell development 
by preventing premature activation and differentiation of GC B-cells as well as by providing 
a suitable environment for further B-cell development [28,156,157]. It can block the terminal 
differentiation by repressing PR domain containing 1 (PRDM1) which encodes Blimp-1, the 
master regulator of plasmacytic differentiation, but can also enable cell-cycle progression by 
repressing cyclin-dependent kinase inhibitors CDKN1A and CDKN1B that induce cell cycle 
arrest [158-160]. Additionally, Bcl-6 is involved in the development of CD4+ Tfh cells, essential 
in GC reaction [161,162]. The main functions of BCL6 are summarized in Figure 3.
Deregulation of BCL6 has been shown to be leukemogenic and to contribute to the 
pathogenesis of DLBCL [153,163]. Aberrations in BCL6 have also been detected in T-DL-
BCL, but their functional role in T-DLBCL remains to be further studied [74]. Translocations 
of BCL6 are shown to be more common in ABC/non-GCB DLBCL with contradictory results 
according to the association with survival when occurring either alone or in combination with 
MYC  translocations [145,164-168]. Co-expression of Bcl-6 and c-Myc has, however, been 
described to translate into worse prognosis, but the association seems to be dependent 
of concurrent Bcl-2 and c-Myc co-expressions [164]. In T-DLBCL, Bcl-6 expression has been 
described to be low (5%) whereas BCL6 has been reported to be frequently (29–48%) rear-
ranged [74,127].
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MYC is an oncogene promoting cell division by several distinct mechanisms including 
direct regulation of its target genes involved in cell proliferation and growth as well as con-
trol of messenger RNA, microRNAs, and apoptosis mediators [169-171]. Expression of MYC 
protein product c-Myc has been detected in up to 70% of all human malignancies [169]. It 
has been shown to be essential for the formation, maintenance, and proper function of GCs, 
and highly leukemogenic at several stages of B-cell maturation [157,169,172,173]. The main 
functions of MYC are summarized in Figure 3.
MYC rearrangements were discovered in BL in the 1980s [174]. They are known to be cru-
cial for lymphoma pathogenesis in BL and in subsets of DLBCL and have been associated with 
poor prognosis in DLBCL [164,168,169,175-177]. MYC rearrangements occur in about 9% 
of DLBCL cases, and 60–80% of patients with a MYC translocation have been reported with 
concurrent Bcl-2 expression [168,175]. Furthermore, translocation of MYC seems to predict 
worse outcome of DLBCL patients especially when occurring concurrently with Bcl-2 expres-
sion [142]. Overexpression of c-Myc has been reported as an adverse prognostic factor among 
immunochemotherapy-treated DLBCL patients [144,146]. No association with a distinct COO 
subgroup has been shown with c-Myc protein expression whereas MYC rearrangements have 
been reported to be more common in GCB phenotype in some studies while other studies 
found no association with COO [142,164,168,175,178]. In T-DLBCL, only 6% of the cases have 
been reported with MYC rearrangements and 13% of the cases with positive c-Myc expres-
sion, and the role of MYC has not been thoroughly studied in T-DLBCL [127].
Figure 3. The functions of BCL2, BCL6, and MYC. The main functions of oncogenes BCL2 
and MYC as well as transcription factor BCL6	are	summarized	in	the	figure.
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When occurring together with translocation of MYC, translocations of BCL2 or BCL6 
lead	 to	 a	 manifestation	 of	 aggressive	 double-hit	 lymphomas	 with	 reportedly	 significantly	
worse outcome, especially in DLBCL with concurrent translocations of MYC and BCL2 
[130,142,143,164,168,179-186]. About 60% of double-hit lymphomas have MYC and BCL2 
translocations while translocations of MYC and BCL6 cover about 20% of double-hit lym-
phomas; about 20% of the cases have concurrent translocations of all MYC, BCL2, and BCL6 
(triple-hit lymphomas) translating into a most dismal outcome [176,181,182,187].
The majority of double-hit lymphomas represent GCB phenotype and over 65% of the 
cases have been reported with extranodal lymphoma involvement, most often involvement 
of the bone marrow or the CNS [144,164,180,181,185,186,188]. As majority of T-DLBCLs rep-
resent ABC phenotype, the frequency of BCL2 and MYC rearrangements in T-DLBCL is com-
parable to nodal ABC-DLBCL (about 10% and 15%, respectively), while BCL6 rearrangements 
seem less common in T-DLBCL (about 40% in T-DLBCL vs. 60% in nodal ABC-DLBCL) [73].
Cases with c-Myc and Bcl-2 or Bcl-6 protein expression have been named ‘double-ex-
pressers’, and cases with expression of M-myc, Bcl-2, and Bcl-6 correspondingly ‘triple-ex-
pressers’ [6]. In nodal DLBCL, double-expressers are more prevalent than double-hit lym-
phomas (20–30% vs. 5%, respectively) [109,142,144,176,178,189]. Double-expressers most 
commonly	Represent	ABC/non-GCB	phenotype	and	associate	with	significantly	increased	risk	
of CNS relapse and shorter survival, contributing to the overall inferior prognosis of ABC 
phenotype [109,142,145,178, 189-192]. The frequency of double-expressers among T-DLBCL 
cases has, however, been reported to be markedly lower, about 13% [127].
2.3.3 Genetic landscape
Besides the COO-based division into ABC or GCB phenotype, recent genetic studies on 
DLBCL have been able to identify other additional phenotypically distinct DLBCL subtypes 
with different genetic aberrations, gene-expression signatures, and responses to immuno-
chemotherapy [146,193,194]. Regarding aberrations in individual genes, mutations in driver 
genes such as MYC and CD79B have been associated with poor survival whereas mutations in 
NF1 and SGK1 have been shown to associate with favorable outcome in DLBCL [146].
The genetic features generally associated with ABC-DLBCL are summarized in Table 7. They 
include increased activation of the NF-κB pathway through mutations of CARD11 and MYD88 
(in 10% and 29–33% of ABC-DLBCLs, respectively) as well as mutations of CD79B (in 12–18% 
of ABC-DLBCLs), IRF4, EBF1, and MALT1, with mutations of MYD88 and CD79B often coexist-
ing (in >50% of the cases) and basically excluding translocations of BCL2 and MYC [36,45,47, 
49,53,63,64,113,146,188]. Genetic alterations in genes such as PAX5, CDKNA2, KLHL14, and 
BTG1 have been shown to associate with poor survival whereas alterations in CREBBP have 
been associated with favorable survival in ABC-DLBCL [146].
Though the majority of T-DLBCLs represent the ABC phenotype, the genetic features 
of T-DLBCL seem to differ from other common ABC-DLBCL entities with some unique com-
binations of genetic alterations shared with PCNSL [74,103]. In T-DLBCL, MYD88 muta-
tions have been detected in 68–82% of the cases and CD79B mutations in 19–44% of the 
cases, with 94–100% of CD79B mutations occurring concurrently with MYD88 alterations 
[74,188,195,196].	 Amplifications	 of	NF-κB inhibitor Zeta (NFKBIZ) have been described in 
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44% of T-DLBCL cases, leading to increased expression of inhibitor of nuclear factor kappaB 
Zeta (IκB-ζ), another essential NF-κB pathway-activating protein in ABC-DLBCL [74,197,198]. 
Loss of CDKN2A	has	been	shown	to	be	significantly	more	common	in	T-DLBCL/PCNSL	than	in	
nodal ABC-DLBCL (71% vs. 34.5%, respectively) with increased number of total copy number 
alterations indicating genetic instability [74].
Significantly	higher	load	of	IgVH	SHMs	has	been	reported	in	T-DLBCL	compared	to	nodal	
ABC-DLBCL [103]. Upregulation/rearrangements of forkhead box P1 (FOXP1), an oncogene 
suppressing B-cell apoptosis, and high expression of its protein FoxP1 as well as choline trans-
porters-like protein 1 (CTL1), involved in RNA processing, have been detected in T-DLBCL 
[103,199-202]. Mutations of MALT1 have been reported in at least one T-DLBCL case [203]. 
Additionally, frequent copy number alterations and translocations of 9p24.1 (coding PD-L1/
PD-L2)  as well as more common loss of HLA	genes	have	been	identified	in	both	T-DLBCL	and	
PCNSL compared to nodal ABC-DLBCL [74,91,92,199,204-206].
Several distinct genes have been reported to be differentially expressed in T-DLBCL 
compared	to	other	extranodal	and	nodal	ABC-DLBCLs	[103].	In	line	with	mutational	findings	
described earlier, increased mRNA expression levels of genes such as CARD11 and MYD88 
have been detected in T-DLBCL [103,196]. Expression levels of other genes involved in signal-
ing pathways, cell growth regulation, DNA repair, and cellular metabolism have been reported 
to be either higher or lower in T-DLBCL compared to other extranodal ABC-DLBCLs whereas 
expression levels of HLA genes as well as genes encoding various extracellular matrix pro-
teins, adhesion molecules, and molecules involved in cytoskeletal reorganization have been 
described	 to	 be	 lower	 in	 T-DLBCL	 [103,207,208].	 As	 a	 conclusion,	 the	 genetic	 findings	 in	
T-DLBCL	in	general	highlight	significant	NF-κB/TLR-mediated signaling, often with concurrent 
BCR pathway activation.
2.4 Tumor microenvironment (TME)
The TME of B-cell lymphomas consists of several different immune cell subpopulations, includ-
ing TILs, TAMs, NK cells, and DCs, in addition to blood vessels and extracellular matrix [38]. 
The	innate	aim	of	tumor-infiltrating	immune	cells	is	to	induce	anti-tumor	immune	response.	
Tumor cells, however, have several mechanisms to escape this immune response, giving the 
tumors a growth advantage [20,209]. Increasing evidence has demonstrated host immune 
response predicting the outcome of lymphoma patients. In indolent lymphomas, the prog-
nostic value of TILs was recognized already in the 1980s [210,211]. Thereafter, several studies 
have been published on host T-cell immune response, TILs, and TAMs in aggressive lympho-
mas, and the possible mechanisms behind tumor immune escape are beginning to be uncov-
ered [38,212-223]. Since this thesis is addressed on T-DLBCL, the subsequent literature review 
on TME is mainly focused on DLBCL and T-DLBCL.
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2.4.1 Tumor-infiltrating lymphocytes (TILs)
TILs have a dominant role in developing host immune response against tumor cells [209,224-
226]. To initiate the cellular immune response, MHC proteins are needed for antigen pres-
entation as MHC proteins present antigens to T-cells through T-cell receptor (TCR) [227]. MHC 
class I proteins HLA-A, HLA-B, and HLA-C are coded by the corresponding HLA class I genes 
(HLA-A, HLA-B, and HLA-C, respectively), are expressed on all nucleated cells, and are respon-
sible for antigen presentation to CD8+ T-cells [227]. The regulation of MHC class II expression 
is more complicated, and several HLA class II protein coding HLA class II genes such as HLA-
DQA1, HLA-DRB1, HLA-DPA1, and HLA-DQB1 have been recognized [228]MHC class II, con-
sisting of HLA class II proteins, is expressed only on APCs such as DCs, B-cells, monocytes, 
and macrophages and present antigens to CD4+ T-cells [227].
TILs can be divided into CD4+ T-cells (mainly T helper cells (Th cells) and regulatory T-cells 
(Tregs)) and CD8
+ T-cells (mainly cytotoxic T-lymphocytes (CTLs)). Activation of both CD4+ and 
CD8+ T-cells occurs mainly in lymph nodes and requires proper antigen presentation by DCs via 
MHC class I and MHC class II, with an additional co-stimulatory signal mediated by B7-CD28 
interaction [225,229]. Subsequently, the activated T-cells migrate to their target tissue in order 
to perform their effector functions [229]. The mechanisms of T-cell activation, migration, and 
function are complex, and the main characteristics of these mechanisms are described in more 
detail below. The most important features of T-cell activation are also presented in Figure 4.
Figure 4. The activation of CD4+ T-cells and CD8+ CTLs. The activation of both CD4+ T-cells 
as well as CD8+ CTLs requires antigen presentation by DCs via MHC class I and MHC class II 
proteins that present antigens to T-cells through TCR, as well as an additional co-stimulatory 
signal through B7-CD28 interaction. Adjusted from Borst et al. 2018 [231].
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2.4.1.1 CD4+ T-cells, T helper cells
CD4+ T-cells represent a heterogeneous group of immune cells with a wide spectrum of dis-
tinct functions including antigen recognition, immune response activation, as well as immune 
response downregulation [232]. In the TME, CD4+ T-cells can regulate tumor cell function 
directly by eliminating tumor cells or indirectly by modulating the TME [231,233].
The division of CD4+ T-cells into different subtypes has been acknowledged since the 
1980s when two distinct subtypes of CD4+ T-cells with different cytokine production were 
recognized	[234].	Thereafter,	additional	evidence	has	demonstrated	more	specific	subtypes	
that can be either distinguished into different mature cell lineages already in the thymus, such 
as Tregs, or can later differentiate from naïve CD4
+ T-cells, such as Th cells (Th1, Th2, Th3, and 
Th17) and induced regulatory T-cells (iTregs) [232,235-238]. The differentiation of CD4
+ TILs is 
regulated by cytokines and the migration to TME by molecules like L-selectin (CD62L), Figure 
5 [239]. In the next chapters, the activation and differentiation of distinct CD4+ TILs, especially 
Th1 cells, are reviewed.
Figure 5. Differentiation of the main CD4+ T-cell subpopulations. CD4+ T-cell subtypes 
can be distinguished into different mature cell lineages already in the thymus or can later 
differentiate from naïve CD4+ T-cells. The differentiation of distinct CD4+ T-cell subpopulations, 
with	distinct	cytokine	production,	is	regulated	by	cytokines	as	shown	in	the	figure.	
Adjusted from Kennedy et al. 2008 [233].
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Th cells differentiate from naïve CD4+ T-cells and are essential in adaptive immune response. 
They provide help for both B-cells and T-cells and assist in activating and promoting DC mat-
uration and function [232,233]. In the TME, Th cells also promote the priming and activity as 
well as effector and memory functions of CTLs (see section 2.4.1.3 for CD8+ T-cell activation and 
function) [231].
The	first	recognized	Th	cell	subtypes	were	Th1	and	Th2	cells,	with	additional	other	sub-
types with different cytokine production and distinct functions having later been described 
[232,234].	 The	 differentiation	 to	 a	 specific	 Th	 cell	 subtype	 is	 induced	 and	 regulated	 by	
cytokines [240]: T-box expressed in T-cells (T-bet), interferon gamma (INFγ), and interleukin 
12 (IL-12), e.g. regulating the differentiation and survival of Th1 cells, whereas IL-4 induces 
T-cell differentiation towards Th2 cells [232,241-243]. Th1 cells are essential in cell-mediated 
immune response against intracellular pathogens and have a crucial role in effective anti-tu-
mor immunity while Th2 cells drive host defense against extracellular parasites and suppress 
the differentiation of Th1 cells and the function of DCs [232,234,237,244,245]. Since Th1 cells 
are the ones mainly studied in this thesis, the subsequent literature review is focused on Th1 
cells.
The primary inducer of Th1 differentiation is IL-12 produced mainly by APCs and medi-
ated by factors such as signal transducer and activator of transcription 4 (Stat4) [246,247]. The 
functions of Th1 cells are mediated through the production of cytokines such as INFγ, IL-2, and 
tumor necrosis factor beta (TNFβ) [232,241]. INFγ produced by Th1 cells induces macrophage 
activity against microbes, and the activated M1 macrophages produce cytokines such as IL-12, 
further inducing a positive feedback loop of Th1 differentiation [232,248]. INFγ also induce 
IL-12 receptor expression on antigen-activated Th cells, inhibiting their differentiation towards 
Th2 cells [249,250]. Additionally, INFγ produced by Th1 cells induces the differentiation of 
short-lived effector CD8+ T-cells, discussed in more detail in section 2.4.1.3 [243,251].
Although	beneficial	in	infections,	a	deregulated	Th1	response	against	self-antigens	can	
lead to autoimmune disease, and several regulatory mechanisms for the dampening of Th1 
response have been recognized [252]. In addition to self-regulation by IL-10 produced by 
highly activated Th1 cells, other immune cells, such as Tregs, can downregulate the activity 
of Th1 cells [235,253,254]. Tregs, being responsible for the regulation of immune response 
and self-tolerance, are essential for proper regulation of Th1-mediated adaptive immunity, 
and loss of Tregs has been demonstrated to lead to uncontrolled Th1 responses and aggres-
sive autoimmune disease [235,252,255]. As Tregs are a heterogeneous and versatile group of 
immune cells, it has been demonstrated that, during strong Th1 response, Tregs can differen-
tiate into a subgroup of Tregs that express both Forkhead box P3 (FoxP3) and T-bet and are 
optimized for the suppression of Th1 cells [243,252,256]. Differentiation and function of Tregs 
are further discussed in section 2.4.1.2.
T-bet is a transcription factor crucial for Th1 differentiation and commonly recognized as 
a Th1 cell marker [241,242]. In addition to Th1 cells and Tregs, T-bet can be expressed by thy-
mocytes, DCs, NK cells, and innate lymphoid cells [241-243]. The expression of T-bet can be 
induced by TCR, IFNγ-Stat1, or IL-12-Stat4 signaling pathways, with also other mechanism of 
T-bet expression upregulation having been suggested, such as autoactivation of T-bet coding 
Txb21 [241,243,257-259]. Similar to INFγ, T-bet can promote Th1 differentiation as well as 
suppress the development of other Th cell lineages [243]. When co-expressed with FoxP3 in 
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Tregs, T-bet can, however, have also adverse effects with Th1 cell suppressing functions [252]. In 
Th1 cells, T-bet promotes the production of INFγ, introducing yet another self-directing loop 
of Th1 cell differentiation, independent of IL-12 [242].
2.4.1.2 Regulatory T-cells
Tregs	are	involved	in	regulating	immune	response	and	self-tolerance	[235].	They	were	first	rec-
ognized in the 1990s when CD25 expressing CD4+ T-cells were shown to suppress immune 
response and maintain self-tolerance [260]. Later, it has been described that Tregs can be 
divided into CD4+ “natural” Tregs (nTregs) produced by normal thymus and iTregs differentiated 
from naïve CD4+ T-cells [232,235]. These can be further divided into different subgroups with 
distinct functions, and also additional other subgroups of T-cells, such as a subpopulation 
of CD8+ T-cells have been shown to have regulatory functions [236,256]. Furthermore, Tregs 
can emerge to their target tissue through different paths including migration from circulat-
ing blood or the lymphatic system, differentiation resulting from DC activation, and trans-
forming growth factor beta (TGF-β) induced differentiation from naïve CD4+ T-cells into Tregs 
[229,252,256,261-266]. Altogether, several distinct subtypes of Tregs have been described and 
since this thesis mainly studies CD4+FoxP3+ Tregs, the following literature review is focused on 
describing	the	function	and	regulation	of	this	specific	subtype	[236,256].
FoxP3 is a transcription factor expressed in CD4+ Tregs and tumor cells [236,266,267]. It is 
known as the key regulatory gene in the development of nTregs and is a commonly recognized 
Treg marker [266-268]. The expression of FoxP3 is essential in maintaining the suppressive 
activity of Tregs, and in case of a strong Th1 response, INFγ-mediated additional expression 
of T-bet is required for the proper migration and maintaining of the functional capability of 
Tregs [243,252,269]. The expression of FoxP3 in Tregs can be regulated by different signaling 
pathways, such as TCR and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mamma-
lian target of rapamycin (mTOR), epidermal growth factor receptor (EGFR)/glycogen synthase 
kinase 3 beta (GSK-3β)/FoxP3, hypoxia-inducible factor-1 alpha (HIF1A), and others [267,270-
276]. In addition, TGF-β expressed by another Treg subtype, Th3 cell, can induce the differenti-
ation of naïve CD4+ cells into CD4+FoxP3+ iTregs through IL-2-Stat5 pathway [263-265,277,278]. 
CD4+FoxP3+ Tregs suppress immune response against self-antigens and tumors and 
have been demonstrated to suppress the function of other CD4+ TILs as well as other 
anti-tumor immune response cells such as NK cells, macrophages, DCs, and B-cells 
[212,232,236,256,267,279]. The immune suppressive functions of Tregs can occur through sev-
eral different mechanisms including the secretion of inhibitory cytokines and other molecules 
such as TGF-β, IL-10, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte-ac-
tivation gene 3 (LAG-3), and granzyme B (GrB) [279]. Additionally, IL-10 produced by Tregs 
may upregulate the expression of inhibitory programmed cell death ligand 1 (PD-L1) on DCs, 
leading to CTL exhaustion (see section 2.4.1.4 for T-cell exhaustion) [280].
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2.4.1.3 CD8+ T-cells
CD8+ TILs have a dominant role in cell-mediated anti-tumor immune response [229]. In the 
TME, CD8+ CTLs detect intracellular antigens presented by MHC I molecules on all tumor 
cell types and are responsible for killing the tumor cells by granule exocytosis and Fas ligand 
(FasL)-mediated apoptosis induction [229,281]. Additionally, CTLs interact with other immune 
cells of the TME by producing cytokines such as INFγ and tumor necrosis factor alpha (TNFα) 
[281].
The optimal function of CD8+ TILs requires their attachment to endothelial cells, followed 
by their proper migration and differentiation, and is regulated by several different mechanisms 
[229,239,282-284]. CD8+ TILs are recruited to tumor site from peripheral blood by cytokines 
such as IL-12, chemokine (C-C motif) ligands 4 and 5 (CCL4 and CCL5), and chemokine (C-X-C 
motif) ligands 9, 10, and 11 (CXCL9, CXCL10, and CXCL11) [229]. The migration of CD8+ TILs 
to the TME is regulated by molecules like CD62L, enabling the attachment of CD8+ TILs to 
endothelial cells [239]. Myeloid-derived suppressor cells (MDSCs) can, in contrast, downregu-
late the migration by mechanisms including the reduction of IL-12 secretion and the suppres-
sion of CD62L expression in both CD4+ and CD8+ T-cells [239,285].
Traditionally, CD8+ T-cells have been divided into effector T-cells and memory T-cells: 
effector T-cells being the ones active in acute infections and vaccinations with the requirement 
of antigen presentation by DCs and the co-stimulatory signal through the B7-CD28 pathway 
to be activated; memory T-cells being T-cells that can remain after the ongoing antigen pres-
entation	and	 inflammation	has	ceased	and	again	be	 re-activated	upon	 re-stimulation	 [286-
289]. In the TME, with continuous antigen exposure, the evolution of CD8+ T-cells is different 
and the majority of effector cytotoxic T-cells have been shown to obtain a state of exhaustion 
instead of converting into memory T-cells (see section 2.4.1.4 for T-cell exhaustion) [288,290]. 
In previous literature, also Th cells and memory T-cells are considered as effector T-cells along-
side	with	CTLs	 [229,232].	For	clarification,	 in	 this	 literature	 review,	 the	term	CTL	 is	used	to	
specify a subset of CD8+ TILs with cytotoxic activity instead of using the term effector cytotoxic 
T-cell. T-cell exhaustion is reviewed in more detail later in section 2.4.1.4 whereas this chapter 
describes the regulation of CD8+ TIL activation and function.
CTLs are a subset of differentiated CD8+ effector T-cells that are essential in immune 
response against tumor cells. As described earlier in section 2.4.1, the activation of CTLs, 
so-called ‘T-cell priming’, requires both antigen presentation and a co-stimulatory signal from 
DCs, Figure 4. Additionally, CTL-mediated anti-tumor immune control is assisted by essential 
help	 from	Th	 cells,	mediated	by	 a	 specific	gene	program	 that	 downregulates	 coinhibitory	
receptors such as PD-1 and increases the motility and migration capacities of CTLs by induc-
ing the expression of chemokine receptors and metalloprotease activity [251]. The activa-
tion of Th cells also assists DCs in both optimizing antigen presentation to CTLs as well as 
in promoting CTL clonal expansion and differentiation by releasing cytokines and delivering 
co-stimulatory signals [231,251,291].
The help from CD4+ T-cells is largely mediated via CD70–CD27 interaction although sev-
eral other mechanisms and pathways also exist, Figure 6 [251]. The simultaneous activation of 
CD4+ and CD8+ T-cells leads to expression of CD40L on activated CD4+ Th cells [292]. CD40L 
interacts with CD40 on DCs, further activating the upregulation of CD80, CD86, and CD70 
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in DCs and triggering the co-stimulatory receptors CD27 and CD28 on CD8+ CTLs [251,293-
295]. The subsequent CD70–CD27 interaction leads to activation of CTLs. It has been dis-
cussed whether CD40L can also directly stimulate CTL differentiation by binding to CD40 in 
CTLs, but the reports on this have been inconsistent [291,296-299]. Additionally, interactions 
between DCs and NK cells seem to be able to substitute Th-mediated help by stimulating 
Th1- and Th2-related cytokine release from NK cells, and lack of help from CD4+ Th cells has 
been associated with lower expression of killer cell lectin-like receptor G1 (KLRG1), CD127, 
INFγ, GrB, and T-bet [251,300,301].
Stimulation by extracellular cytokines such as IL-2, IL-7, IL-15, and IL-21 can promote the 
activation of CTLs, and as with CD4+ T-cells, CTLs can also induce their own activity by secret-
ing cytokines such as IL-12 and INFγ, promoting the differentiation of CD8+ T-cells into effector 
CTLs [229,231]. Additionally, CTLs express several co-stimulatory and inhibitory receptors that 
can further modify their activity [302-304].
Figure 6. The activation of CTLs. The simultaneous activation of CD4+ and CD8+ T-cells leads 
to the expression of CD40L on activated CD4+ Th cells. CD40L interacts with CD40 on DCs, 
and further activates the upregulation of CD70 in DCs and triggers the co-stimulatory receptor 
CD27 on CD8+ CTLs. Cytokines such as IL-2, IL-12, IL-15, and IL-21 can further promote the 
activation and differentiation of CTLs. 
Adjusted from Borst et al. 2018 [231].
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In the TME, activated CTLs kill tumor cells by granule exocytosis and FasL-mediated 
apoptosis. The granule exocytosis pathway is activated by granzymes A and B (GrA and GrB) 
released by CTLs [305-308]. The released granzymes enter tumor cells and lead to their death 
by several distinct mechanism, including the induction of DNA damage, loss of cell membrane 
integrity, and destruction of nuclear envelope [305,306,309]. The FasL pathway of apoptosis is 
mediated by CTL activation of FasL, leading to subsequent cytochrome c release in the target 
cells,  activation of caspases, and tumor cell apoptosis [309,310]. In addition, cytokines such 
as IL-2, INFγ, and TNFα released by CTLs can induce the anti-tumor activity of other immune 
cells such as M1 macrophages as well as their cytotoxicity against tumor cells (discussed in 
more detail in section 2.4.2) [311-313].
2.4.1.4 T-cell exhaustion
The primary role of TILs is to induce anti-tumor response. The TME, however, serves a distinct 
milieu for T-cells to function as the antigen exposure is prolonged and antigen removal unsuc-
cessful,	 leading	to	a	state	of	exhaustion	that	was	first	recognized	in	viral	 infections	and	has	
thereafter been described in tumors [314-319]. In recent years, knowledge on tumor biology 
and	T-cell	exhaustion	has	 increased	and	led	to	major	advancements	 in	the	medical	field	as	
immune checkpoint inhibitors are already commonly used in the treatment of many malignan-
cies including lymphomas. In this chapter, the mechanisms of T-cell exhaustion are selectively 
reviewed, focusing on the interactions between the tumor and the host immune cells, inhibi-
tory	receptors,	cytokine	milieu,	and	other	inflammatory	cells,	leaving	out	a	thorough	descrip-
tion of the metabolic conditions and other environmental issues in the TME also involved in 
T-cell exhaustion [230].
Tumor cells have several mechanisms of escaping the T-cell-mediated anti-tumor immune 
response. The mechanisms include direct interactions between tumor and host immune cells, 
altered expression of surface molecules, and recruitment of immunosuppressive cells that 
downregulate T-cell activation [38,223,225,230,320-324]. In CTLs, T-cell exhaustion leads to 
upregulation of inhibitory receptors, decreased production of effective cytokines, and reduced 
cytotoxic activity and proliferation [230]. The activation of naïve T-lymphocytes against tumor 
cells	is	also	impaired	by	inadequate	tumor-specific	antigen	presentation	and	by	downregula-
tion of CTL activation, mediated by other host immune cells [230].
The interactions between tumor cells and CTLs is altered by different mechanisms lead-
ing to impaired CTL activation and function as well as induced apoptosis of CTLs [230,325]. 
Tumor cells express molecules such as programmed death cell ligand 1 (PD-L1) and FasL 
[310,321].	The	expression	of	PD-L1	has	been	associated	with	decreased	infiltration	of	CTLs	
and has been suggested to induce CTL apoptosis [230,320]. Nevertheless, further studies 
have shown PD-L1 expression associating with immune escape and T-cell non-responsiveness 
rather than apoptosis induction [209,288]. The function of FasL depends on the microenviron-
ment	[310,324].	It	can	both	promote	anti-inflammatory	and	anti-tumor	responses	and	induce	
apoptosis of CTLs [310,324,325].
Exhausted phenotype T-cells express inhibitory receptors such as PD-1, LAG-3, T-cell 
immunoglobulin and mucin domain containing-3 (TIM-3), and CTLA-4 [230,288,317,318,326-
328]. In normal conditions, the initial purpose of these inhibitory receptors is to downregulate 
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excessive immune response, autoimmune activity, and tissue damage. In the TME, however, 
the activation of inhibitory pathways leads to impaired immune response, T-cell exhaustion, 
further induction of the expression of these inhibitory receptors, and gradual loss of the ability 
of CTLs to produce cytokines such as IL-2, TNFα, INFγ, and GrB [230]. Both the overexpression 
of inhibitory receptors and decreased cytokine production have been shown to increase in line 
with prolonged antigen exposure [314]. The functions of PD-1, LAG-3, and TIM-3 are subse-
quently	briefly	reviewed.	The	activation	and	function	of	CTLA-4	and	other	inhibitory	receptors	
are not further discussed in this review as they were not studied in this thesis.
PD-1	was	first	discovered	in	the	1990s	as	a	gene	upregulated	in	T-cell	hybridoma	under-
going cell death [329]. It is currently known as an inhibitory receptor expressed predominantly 
by TILs and can also be expressed by B-cells and other immune cells [321,330]. Its ligands 
PD-L1 and PD-L2 can be expressed by tumor cells as well as other cells in the TME [331-333]. 
In normal conditions, the expression of PD-1 is induced following TCR engagement, and is 
eventually reduced as the antigen exposure ceases [230,321]. In tumors, antigen exposure 
is prolonged, leading to sustained PD-1 expression on TILs, and the PD-1–PD-L1 interaction 
between CTLs and tumor cells has been shown to be one of the hallmark pathways in T-cell 
exhaustion [209,321]. The mechanisms of PD-1-mediated T-cell downregulation are not fully 
understood but alterations such as modulation of TCR signaling and PI3K/AKT/mTOR path-
way have been suggested [230]. On the other hand, the effect of PD-1-targeted therapies 
has been shown to be CD28-dependent, demonstrating that PD-1-mediated T-cell inhibition 
mainly occurs through inactivation of the co-stimulatory CD28-B7 signaling [334-336].
LAG-3 is an MHC II ligand expressed on activated and exhausted T-cells, B-cells, and DCs 
[230,337-339]. It enables the maintenance of tolerance to self and tumor antigens by directly 
suppressing the activity of CD8+ T-cells [340]. It has been reported to function synergistically 
with other inhibitory receptors such as PD-1 in promoting T-cell exhaustion [341,342]. Addi-
tionally, LAG-3 suppresses CD4+ T-cell expansion, promotes the function of Tregs, and modu-
lates the activity of DCs [337,338,343-345]. It has been suggested as a marker for Tregs and 
their activity [344]. The LAG-3-induced modulation of DC function is mediated by upregula-
tion of co-stimulatory molecules and by production of IL-12 and TNFα, leading to DC matu-
ration and activation [345].
TIM-3 is an immunoregulatory checkpoint receptor expressed by most lymphocyte sub-
types including exhausted T-cells and NK cells and is regulated similarly to PD-1 [230,346,347]. 
The expression of TIM-3 leads to inadequate T-cell function and decreased production of 
cytokines such as IL-2, TNF, and INFγ [348-350]. On TILs, the expression of TIM-3 seems to 
enhance T-cell exhaustion when co-expressed with PD-1 [348]. 
T-cell exhaustion can be mediated by cytokines produced by tumor cells, TAMs, or Tregs 
[230,351]. Cytokines such as TGF-β and IL-10 downregulate T-cell activity and modulate the 
activity of other immune cells while IL-12 has been reported to induce T-cell exhaustion by the 
induction of LAG-3 and TIM-3 [230,352,353].
Interactions between CTLs and other immune cells are complex, and CTLs can both antag-
onize and support the activity of Tregs [313]. As described earlier in section 2.4.1.3, CD4
+ Th 
cells are crucial in CTL activation and downregulation of T-cell exhaustion [231]. CD8+ T-cells 
primed in the absence of CD4+	Th	cells	have	been	shown	to	express	significantly	higher	levels	
of co-inhibitory receptors such as PD-1, BTLA, LAG-3, and CD200 receptor (CD200R) (and 
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its	ligand	CD200)	and	have	significantly	less	cytotoxic	activity	than	CD8+ T-cells primed with 
help from CD4+ Th cells [251]. The activity of CD8+ T-cells primed without help from CD4+ Th 
cells	could,	however,	be	improved	with	specific	anti-PD-1,	anti-BTLA,	and	anti-LAG-3	mAbs,	
indicating a reversible inhibition of these receptors [251].
2.4.2 Tumor-associated macrophages (TAMs)
Macrophages are an essential part of both innate and adaptive immune systems with their 
capability of phagocytosis and the ability of inducing T-cell activation and recruitment. Clas-
sically, macrophages have been divided into two subtypes which can roughly be described 
as tumor suppressive, classically activated M1 macrophages and pro-tumor, alternatively 
activated M2 macrophages [354-356]. Nonetheless, macrophages are a heterogeneous and 
flexible	group	of	cells	that	can	modify	their	phenotype	according	to	the	surrounding	microen-
vironment [357-361]. Growth factors, cytokines, and chemokines drive the differentiation of 
macrophages, and especially the alternatively activated M2 macrophages can be further 
divided into different subtypes with distinct functions [355,362-367].
Macrophages are phagocytic cells, present in basically all tissues, and have a role in 
immune responses as well as in maintaining metabolic homeostasis [362]. They derive from cir-
culating peripheral-blood mononuclear cells that develop from common myeloid progenitor 
cells in the bone marrow [363,368]. The common myeloid progenitor cells (granulocyte/mac-
rophage colony-forming units) undergo differentiation into monoblasts, pro-myelocytes, and 
finally	monocytes	before	leaving	the	bone	marrow	and	entering	the	peripheral	blood	[363].	
Monocytes from peripheral blood migrate to tissues, developing further into macrophages or 
DCs [363,369]. The differentiation is induced by cytokines such as IL-10 which promotes the 
differentiation towards macrophages and inhibits the differentiation towards DCs [370,371]. It 
has been suggested that monocytes could mature and differentiate also in the bloodstream, 
and	the	point	of	recruitment	to	the	tissue	during	this	maturation	could	define	their	function	in	
the tissue [362]. Additionally, populations of mature macrophages in the tissue may also arise 
through proliferation of tissue-resident colony-forming cells [362,363].
The role of macrophages in maintaining metabolic homeostasis includes removal of cellu-
lar debris generated by either tissue remodeling, necrosis caused by stress or trauma, or cells 
that have undergone apoptosis [362]. Macrophages recycle the material to be reused by the 
host, and the material phagocytosed by macrophages can alter their physiology by causing 
changes to their expression of surface molecules as well as the production of cytokines and 
other	inflammatory	mediators	such	as	TGF-β, TNFα, and ILs [362,372-374]. The endogenous 
danger signals (proteins, histones, DNA and other nucleotides, components of the extracel-
lular matrix) phagocytosed along with cellular debris are detected by macrophages through 
receptors such as TLR, intracellular pattern-recognition receptors, and interleukin-1 receptor 
(IL-1R), further inducing macrophage activity [375-377]. The induced macrophage activation 
can	either	initiate,	enhance,	or	inhibit	inflammation	through	various	signaling	pathways	includ-
ing the NF-κB pathway [376,377]. This macrophage activation is independent of adaptive 
immune	response,	indicating	a	significant	role	of	macrophages	in	detecting	possible	danger	
and participating in both innate and adaptive immune responses [372,376]. Additionally, the 
phenotype and physiology of macrophages can be altered by signals from both innate and 
32 TESTICULAR DIFFUSE LARGE B-CELL LYMPHOMA; PROGNOSTIC CLINICAL, MOLECULAR, AND IMMUNOLOGICAL FACTORS
adaptive immune responses that can either enhance or downregulate macrophage activity 
[362]. The most important features of macrophage differentiation and activation are presented 
in Figure 7.
Figure 7. Macrophage differentiation. Macrophage activation can either initiate, enhance, or 
inhibit	inflammation,	and	macrophages	can	be	divided	into	different	subtypes	with	alternative	
functions. The phenotype and physiology of macrophages can, however, be altered by signals 
from both innate and adaptive immune responses. The factors inducing the activation of 
different	macrophage	subtypes	with	distinct	functions	are	described	in	the	figure.	
Adjusted from Gordon et al. 2005 [363].
M1 macrophages are produced either during cell-mediated immune response or in 
response	 to	 innate	 stimuli	 from	stress	 reaction	or	 viral	 infection	 [362].	They	are	defined	as	
classically activated phenotype with potent microbicidal properties and capability to produce 
IL-12 and promote IL-12-mediated Th1 cell response (Th1 cells are reviewed more closely 
in section 2.4.1.1) [366,367]. They are also highly capable of functioning as APCs [378]. The 
activation of M1 macrophages is induced by factors such as INFγ, TNFα, and lipopolysaccha-
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rides (LPS) through several possible mechanisms [366,367,378]. Innate immune cells such as 
NK	cells	can	induce	macrophages	in	their	killing	ability	and	the	production	of	pro-inflamma-
tory cytokines by producing INFγ as an early response to infections, whereas more sustained 
production of INFγ by the adaptive immune response-mediating Th1 cells maintains M1 
activity and enables a stable host defense against intracellular pathogens [362]. Since TAMs 
are considered to mainly represent the alternatively activated phenotype, the other possible 
mechanisms of M1 activation are not described here in more detail, and the subsequent liter-
ature review is focused on the M2 phenotype [362].
Alternatively activated M2 macrophages can be further divided into different subgroups 
with distinct activating stimuli and functions [366,367]. Exposure to IL-4 or IL-13 activates 
macrophage differentiation towards a distinct phenotype that can be named M2a; exposure 
to	 immune	 complexes	 together	 with	 pro-inflammatory	 stimuli	 such	 as	 LPS	 differentiation	
towards another phenotype, M2b; and exposure to IL-10, TGF-β, or glucocorticoids towards 
yet another different phenotype, named M2c; Figure 7 [366,367]. Additionally, IL-6 and leu-
cine-rich repeat-containing G-protein-coupled receptor (Lgr4) mediated signaling have been 
demonstrated to be involved in M2-like differentiation of TAMs [360,379].
The differentiation of so-called wound healing M2a macrophages is considered to be 
mainly induced by the adaptive immune response [362]. Tissue injury leads to activation of 
IL-4- and IL-13-mediated Th2 response and further activation of M2a macrophages [380,381]. 
M2a macrophages secrete components of extracellular matrix, suppress the clonal expansion 
of	neighboring	lymphocytes,	and	are	less	efficient	at	producing	pro-inflammatory	cytokines	
and at killing intracellular pathogens than M1 macrophages [362]. They also lack the ability to 
induce T-cell activation and have been shown to present with decreased production of both 
Th1 cell-inducing IL-12 and immunosuppressive IL-10 [367].
The	presence	of	immune	complexes	together	with	pro-inflammatory	stimuli	such	as	LPS	
can	induce	macrophage	differentiation	towards	potent	anti-inflammatory	M2b	macrophages	
[367,382]. The IL-4 primed M2a macrophages can also convert into M2b-like phenotype in the 
presence of immune complexes [367]. M2b macrophages present with altered cytokine pro-
duction such as increased production of IL-10 and decreased production of IL-12 [367,382]. 
These M2b macrophages can, however, induce the activation of IL-4-, IL-10-, and IL-13-pro-
ducing Th2 cells [232,367].
In stress reactions, exposure to glucocorticoids can alter macrophage activity by affecting 
Th1/Th2 balance through suppressing the production of Th1 cell inducing IL-12 and shifting the 
balance of adaptive immune response towards Th2 cell activation [383-386]. The phagocytotic 
activity of apoptotic cells of macrophages is retained or increased in response to glucocorti-
coids, leading to their increased secretion of regulatory molecules such as TGF-β [373,387]. 
Additionally, glucocorticoids suppress NF-κB pathway activation and the production of pro-in-
flammatory	cytokines	such	as	IL-1,	IL-6,	and	TNF,	whereas	the	production	of	anti-inflammatory	
cytokines such as IL-10 is increased in response to glucocorticoids [384,388,389]. Exposure to 
regulatory factors such as TGF-β, IL-10, and glucocorticoids induces macrophage differentia-
tion towards regulatory M2c macrophages [362,366]. Analogous to M2b macrophages, M2c 
macrophages	inhibit	inflammation	by	producing	high	levels	of	immunosuppressive	IL-10	and	
by downregulating the production of IL-12 [362,363,390]. They might, however, also retain 
their	ability	to	produce	pro-inflammatory	cytokines	and	present	antigens	to	T-cells	[362].
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TAMs play a crucial role in the TME. They collaborate with B-cells and T-cells through 
direct cell-to-cell interactions as well as through different cytokines, chemokines etc. It seems 
that TAMs may be able to have alternative roles in the tumor depending on their phenotype, 
the TME, and the phase of tumor evolution [351,358,362,378,391-401].
TAMs are often considered to mainly represent M2-like phenotype [351,357]. They 
have been associated with induced tumor angiogenesis and poor prognosis [358,402-404]. 
Some TAMs have been described to share common characteristics with regulatory M2c mac-
rophages, and lower content of TAMs has been reported to have no effect on tumor evolution 
or	to	be	beneficial	to	the	host,	supporting	the	assumption	of	M2c	phenotype	[358,405,406].	
Induced	TAM	infiltration	has,	however,	been	associated	with	both	 increased	tumorigenicity	
and delayed tumor growth while blocking of monocyte recruitment has been demonstrated 
to promote tumor growth [396,397,407,408].
It	seems	that	TAMs	are	a	versatile	population	of	tumor-infiltrating	immune	cells,	and	it	has	
been described that by changes in the TME, TAMs could convert their phenotype from M1 
towards M2c-like during tumor evolution [362,393,399]. TAMs have been shown to secrete 
high	levels	of	pro-inflammatory	TNFα, to eliminate transformed or pre-transformed cells, and 
to be essential in tumor rejection, thereby perhaps being involved in the early tumor evolution 
with M1-like tumor suppressive functions [378,395,409-417]. Later on, M2c-like TAMs can pro-
duce high levels of IL-10, little or no IL-12, and decreased levels of TNFα [351,378,401,409]. 
They suppress the activity of other APCs and have several other pro-tumor functions including 
decreased tumoricidal capacity, downregulation of neighboring TAMs, and the already men-
tioned induction of angiogenesis [362,378,402-404,418].
Altogether,	 TAMs	 are	 a	 highly	 flexible	 immune	 cell	 population	 with	 changing	 roles	
depending on their microenvironment. The interactions between TAMs, tumor cells, and other 
host immune cells are discussed further in section 2.4.3.
2.4.3 Host-related factors and immune escape
The role of host immunity, other host-related factors and immune escape is becoming increas-
ingly acknowledged in many tumors, including lymphoid malignancies [18,38,230,378,419,420]. 
Lymphomas can be seen as a dysfunction of the immune system per se, as they develop from 
immune cells: B-cells, T-cells, or NK cells. The additional changes in the TME lead to a very 
delicate and complex system with numerous different immune cells, cytokines, chemokines, 
receptors, ligands, pathways as well as extracellular matrix and exosomes involved in the tumor 
pathogenesis and evolution [18]. The function and role of B-cells, macrophages, and T-cells 
have been reviewed more thoroughly in sections 2.1, 2.4.1, and 2.4.2, whereas this section is 
focused on summarizing the changes in the TME and the mechanisms by which the tumor can 
alter the functions of the host immune system, further enabling its escape from host immunity.
CTLs are a T-cell subpopulation essential in cell-mediated host immune defense against 
tumor [229,230]. As described earlier in section 2.4.1, the activation and function of CTLs is 
highly complicated and regulated by numerous cytokines, chemokines, and cell-to-cell inter-
actions. The proper activation and function of CTLs require antigen presentation with co-stim-
ulatory signals from DCs as well as help from Th cells or NK cells [251,300]. Conversely, can-
cer-associated	fibroblasts	 (CAFs),	M2-like	macrophages,	 and	Tregs have immunosuppressive 
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functions and can downregulate the CTL-mediated anti-tumor immune response [281]. Addi-
tionally, in the TME, continuous antigen exposure can drive CTLs into a state of exhaustion 
with reduced cytotoxic activity and proliferation [230].
CTLs release factors such as GrA, GrB, TNFα, and INFγ to induce their cytotoxicity against 
tumor cells [281,352]. The same cytokines can induce the activation of other immune response 
cells with anti-tumor activity, such as M1 macrophages [366]. The production of these tumor 
suppressive factors by CTLs can be reduced by immunosuppressive cytokines such as TGF-β 
produced by the tumor cells, Tregs, and M2-like TAMs [230,264,352,366,367,373]. In addi-
tion to tumor progression induction, TGF-β can induce macrophage differentiation towards 
immune-suppressive M2c-like phenotype, promote the immunosuppressive activity of Tregs, 
and suppress the proliferation of CD4+ and CD8+ T-cells [281,366,367,421,422]. Tumor cells 
can also induce the suppression of CTL by secreting factors like adenosine [423-425]. Addi-
tionally, tumor cells can release other immunosuppressive mediators such as PD-L1 and STAT3 
as well as inhibit macrophage polarization towards anti-tumor M1 phenotype by secreting 
factors like tumor-secreted protein S (Pros1) [281,361,426]. Lymphoma cells can further escape 
from macrophage-mediated destruction by CD47-mediated activation of signal regulatory 
protein alpha (SIRPα) [427].
Tregs are immune suppressive cells regulated by several distinct mechanisms of the 
immune system and the TME [428,429]. They reduce responses of both innate and adaptive 
immune systems and collaborate with numerous different immune cell subtypes including M2 
macrophages and CAFs [281,420,430]. They can suppress the activity of CTLs by releasing 
TGF-β and other immunosuppressive factors as well as through adenosine-related pathways 
[281,425,428].
TNFα	has	originally	been	considered	as	a	pro-inflammatory	cytokine	produced	by	mac-
rophages and CTLs [281,409,410]. It induces the anti-tumor functions of several immune cells, 
including M1 macrophages and CTLs [281,354]. Recent observations have, however, also 
revealed possible pro-tumor functions induced by TNFα [281,431]. These observations are 
still preliminary and require additional studies to be thoroughly understood [281].
INFγ	is	another	pro-inflammatory	cytokine	produced	by	NK	cells,	CTLs,	CD4+ T-cells, and 
macrophages [281,362]. It promotes the activation and differentiation of anti-tumor M1 mac-
rophages, Th1 cells, and CD8+ T-cells, inhibits Th cell differentiation towards Th2 cells, but 
also induces PD-L1 and STAT3 expression on M1 TAMs and tumor cells, leading to the expres-
sion of co-inhibitory receptors such as PD-1 on activated T-cells and further T-cell exhaustion 
[232,250,281,366].
Macrophages are part of the innate and adaptive immune systems. They can derive 
into different subtypes with distinct functions according to their microenvironment 
[351,361,378,379,432-434]. TAMs have been demonstrated to have alternative roles 
depending on tumor phase and TME-related factors and seem to be able to convert from 
tumor suppressive M1-like macrophages into pro-tumor M2-like macrophages and vice 
versa [358,378,435-438]. Especially in the early stages of tumor evolution, TAMs have been 
described to have M1-like tumor suppressive functions such as elimination of tumor cells and 
secretion	of	pro-inflammatory	cytokines	like	TNFα [409,410,412-417]. By contrast, TAMs have 
also been demonstrated to be capable of directly promoting tumor angiogenesis as well as 
tumor growth and metastasis [378,404,435,439,440].
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TAMs have been described with decreased ability to lyse tumor cells [404,441,442]. The 
phagocytotic activity of TAMs can be inhibited by NF-κB-regulated expression of immune 
checkpoint molecules such as PD-1 [443,444]. TAMs have been reported to resemble M2 mac-
rophages by their cytotoxicity and the production of cytokines [351,401,442,445]. In addition 
to over-expression of IL-10, the immunosuppressive phenotype of TAMs has been associated 
with defective activation of NF-κB [401,409].
TAMs can have several different mechanisms of regulating T-cell activity [404]. As one of 
the main functions of macrophages is to induce T-cell recruitment and activation, in the TME, 
this function is disturbed by the poor tumor-associated antigen-presenting capability of TAMs 
[404]. Additionally, M2-like TAMs produce high levels of Th1 cell-suppressing IL-10 and shift 
the Th1/Th2 balance towards Th2 cell activation [378]. The IL-10 produced by M2-like TAMs 
further suppresses the effective Th1-CTL-mediated anti-tumor immune response, but can also 
decrease T-cell activation by suppressing the function of other APCs such as DCs [370]. Addi-
tionally, the M2-like TAM induction and increased IL-10 production induces the activation of 
Tregs, leading to further suppression of immune response against tumor [370,446]. 
CD20	targeting	 rituximab	was	 the	first	mAb	 introduced	 in	 lymphoma	treatment.	 It	has	
been demonstrated to accomplish its therapeutic effects through the induction of adaptive 
cellular immune response as both CD4+ and CD8+ T-cells seem to be needed for achiev-
ing treatment response [447,448]. Complement activation, NK cells, neutrophils, and mac-
rophages have also been reported to be involved in the Ab-dependent cell-mediated cyto-
toxicity [449-453]. Interestingly, M2-like macrophages have been shown to phagocytose 
rituximab-opsonized	cells	more	efficiently	than	M1	macrophages	[454].	Anti-CD47	Ab	seems	
to promote the phagocytosis by synergizing with rituximab [455,456].
Increased knowledge on the complexity of the TME and host-related factors involved 
in tumor immune escape are revealing new opportunities to interfere with pro-tumor as well 
as	 tumor-suppressive	 factors	 [18,21,38].	 Immunotherapy	 and	 especially	 host	 T-cell-specific	
immune response promoting therapies have lately been the main focuses of new therapeutic 
approaches in many malignancies including lymphomas [231,281,457-461]. A high number of 
CTLs have been associated with better prognosis of patients, and tumors with high density 
of	CTLs,	so-called	‘immunologic’,	‘hot’,	or	‘inflamed’	tumors,	have	been	reported	to	respond	
better to immunotherapy [281,462-465].
In T-DLBCL, the role of host immunity and immune escape seem to be remarkably impor-
tant [73]. Copy number losses of HLA class I and II leading to decreased expression of MHC I 
and	II	expression	and	limited	tumor-antigen	presentation	to	TILs,	gains	and	amplifications	of	
CD274 and PDCD1LG2 (coding PD-L1 and PD-L2, respectively) with their increased transcrip-
tion and protein expression implicating immune escape, as well as T-DLBCLs’ location in an 
immune-privilege	site	are	all	hallmarks	of	T-DLBCL	and	highlight	the	significance	of	TME	and	
host-related	factors	in	this	specific	lymphoma	entity	[73,74,91,207,466].
As a conclusion, host-related factors and immune escape are extremely eclectic and still 
not fully understood. One of the main functions of tumors seems to be reprogramming of the 
host immune cells in the TME towards immunosuppressive activity. Reduced immunogenicity 
and further immune evasion can also be caused by loss of cell surface molecules and markers 
on tumor cells leading to decreased recognition by host immune cells [18]. The overexpression 
of inhibitory receptors on tumor cells interacting with their counterparts on T-cells can lead 
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to a state of T-cell exhaustion and impaired T-cell-mediated cytotoxicity. Lymphoma cells can 
furthermore have additional mechanisms leading to e.g. their escape of macrophage-medi-
ated immune response. Mechanisms involving NK cells, DCs, and other factors in the TME 
have also been recognized but are left out of this review as they are not in the focus of this 
thesis.
2.4.4 The prognostic value of TME
The prognostic value of numerous distinct factors of the TME has been studied in several 
tumors including lymphomas [419,435,448]. Ratios of T-cell and checkpoint molecule gene 
expression levels have been suggested as prognostic biomarkers in DLBCL, independent of 
R-IPI and COO, as higher proportions of CD4 and CD8 gene expression levels compared to M2 
macrophage and PD-L1 gene expression levels have been reported to correlate with better OS 
[218]. Furthermore, loss of HLA class II gene and protein expressions have been shown to asso-
ciate with lower numbers of CD8+ TILs and worse OS, independent of IPI, among patients with 
DLBCL [227]. Conversely, in T-DLBCL, frequent loss of HLA class I and II protein expressions has 
been reported to associate with higher percentage of CTLs, suggesting that the loss of HLA 
class I and II protein expressions provides a mechanism of immune escape [207].
Based	on	flow	cytometry,	higher	content	of	CD4+ TILs has been demonstrated to predict 
better OS and better event-free survival/relapse-free survival (EFS/RFS) in patients with DLBCL 
treated both in rituximab and pre-rituximab eras, independently of IPI and R-IPI [213,216,217]. 
When studied by IHC in combination with FoxP3 and PD-1, higher content of CD4+, FoxP3+, 
and PD-1+ cells associated with better OS in DLBCL [467]. The same study reported a corre-
lation between the number of CD4+ cells and FoxP3+ and PD-1+ cells but could not localize 
the	expression	of	FoxP3	or	PD-1	to	a	specific	cell	type.	Another	study	showed	that	increased	
infiltration	of	PD-1+ cells had an association with prolonged PFS and OS in DLBCL patients 
treated with R-CHOP but no association with survival according to the proportion of PD-L1+ 
cells could be seen [331,467]. Yet another study, however, reported high PD-L1 positivity of 
the tumor cells predicting inferior OS and associating with non-GCB phenotype and Epstein-
Barr virus positivity in DLBCL [468]. PD-L1 positivity of the TME did not have any association 
to survival in this study, either [468].
Analyzed with IHC, higher FoxP3 positivity has been associated with longer OS of DLBCL 
patients,	 a	 trend	 towards	 longer	 disease-specific	 survival	 (DSS)	 of	GCB	phenotype	DLBCL	
patients, and a trend towards shorter DSS of non-GCB phenotype DLBCL patients, with FoxP3 
positivity, not, however, remaining as an independent prognostic factor in either of these 
studies	 [469,470].	 In	a	study	combining	flow	cytometry,	gene	expression	profiling,	and	cell	
culturing, higher amounts of CD4+CXCR5+FoxP3+ follicular Tregs (Tfregs) were reported to asso-
ciate with limited stage disease and longer complete remission (CR) duration [471]. Based on 
cell culturing examinations, Tfregs were suggested to be involved in intratumoral immunity and 
beneficial	in	DLBCL	[471].
The	prognostic	influence	of	TAMs	in	DLBCL	seems	controversial	[219-222].	In	one	study,	
increased contents of CD68+ TAMs were shown to predict longer OS in immunochemother-
apy-treated DLBCL patients [221]. In line with these results, higher CD68 gene expression 
levels as well as high CD68+ TAM cell contents were reported to associate with longer PFS 
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and OS among immunochemotherapy-treated DLBCL patients also in another study, and the 
prognostic impact on OS was independent of aaIPI [220]. By contrast, higher CD163+ M2 
TAM count and high CD163+/CD68+ ratio were reported to be associated with shorter OS 
and PFS among rituximab-treated DLBCL patients [219,221]. Interestingly, higher content of 
CD68+ TAMs either had no correlation with prognosis or associated with worse survival among 
DLBCL	patients	treated	without	rituximab,	indicating	a	dual,	treatment-specific	role	of	TAMs	
[220,222].	Additionally,	extended	extranodal	involvement,	defined	as	two	or	more	extranodal	
sites, has been reported to be more common in patients with high M2 TAM count [219].
Based on current knowledge on tumor biology and tumor immunity, the role of immune 
checkpoint inhibitors and other TME-targeting therapies has been widely studied in solid tum-
ors and lymphomas including DLBCL [472-475]. Their role in the treatment of T-DLBCL has not 
been established; however, preliminary data on PD-1 blockade in one T-DLBCL patient with 
CNS relapse has shown promising results, with further studies ongoing [476].
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3 Aims of this study
T-DLBCL is a rare and aggressive lymphoid malignancy with dismal prognosis and a high recur-
rence rate. Due to the lack of prospective randomized clinical trials the evidence on different 
treatment	modalities	has	been	frail.	The	role	of	TME,	more	specifically	TAMs,	TILs,	and	T-cell	
exhaustion, has been uncharacterized. The aim of this study was to evaluate treatment results 
of T-DLBCL patients and determine the clinical impact of TME in T-DLBCL.
The	specific	aims	of	this	work	were:
1. to analyze the effect of different treatment modalities on the survival and CNS relapse rate 
of patients with T-DLBCL in a Nordic patient cohort (I). 
2.	 to	study	the	cellular	and	molecular	immunological	profiles	of	the	tumor	tissue	of	T-DLBCL	
patients	and	associate	the	findings	with	patient	survival	(II).
3. to characterize different TIL phenotypes and their possible association with clinical risk 
factors and survival in patients with T-DLBCL (III).
4. to investigate whether the relative expression of immune checkpoint molecules by tumor 
cells	and	tumor-infiltrating	immune	cells	associates	with	survival	in	patients	with	T-DLBCL	
(IV).
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4 Material and methods
This thesis was conducted as a Nordic collaboration study between Denmark and Finland with 
patients from the Danish lymphoma registry and three university hospitals in Southern Finland.
4.1 Patients
This thesis work includes four retrospective population-based substudies (I-IV), one of which 
was conducted as a Nordic collaborative study (substudy I). T-DLBCL patients diagnosed 
between the years 1987–2013 were searched from the Danish lymphoma registry and the 
pathology databases of three university hospitals in southern Finland: Helsinki, Tampere, and 
Turku University Hospitals (substudy I) [477]. Three translational studies (substudies II-IV) were 
conducted	on	tumor	tissue	of	the	same	T-DLBCL	patients	identified	from	the	pathology	data-
bases of Helsinki, Tampere, and Turku University Hospitals. Only patients with DLBCL and 
lymphoma involvement of the testis at diagnosis were included. Patients with primary CNS 
lymphoma involvement at diagnosis were excluded.
4.1.1 Nordic collaborative study (I)
For the patient selection in the Nordic collaborative study, T-DLBCL patients were searched 
from the Danish lymphoma registry and the pathology databases of three university hospitals 
in southern Finland (see section 5.1). Clinical data was collected from the Danish national lym-
phoma registry (Danish patients) and patient records (Finnish patients) [477].
4.1.2 Translational studies (II-IV)
Formalin-fixed,	paraffin-embedded	(FFPE)	tumor	tissue	biopsies	of	primary	diagnostic	orchi-
ectomy samples were collected from local biobanks for the Finnish patients included in this 
study. The samples were utilized in translational studies (substudies II-IV) with minor variations.
With	the	aim	of	exploring	cellular	and	molecular	immunological	profiles	in	actively	treated	
T-DLBCL patients, we selected the patients treated with anthracycline-based chemotherapy 
for the analysis (substudy II). For comparison, we used a dataset of primary DLBCL patients 
from the database of Genotypes and Phenotypes study accession: phs000532.v2.p1 (CGCI) 
[478].
To study TAM and TIL contents and to further characterize their immunophenotypes and 
to	associate	the	findings	with	disease	characteristics	and	survival,	we	included	all	Finnish	T-DL-
BCL patients with tumor tissue available in these studies (substudies III-IV).
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4.2 Study design and biological analyses
Data of T-DLBCL patients was retrospectively collected and organized for the analyses. Differ-
ent treatment modalities as well as baseline clinical factors were recorded. The clinical patient 
data was utilized in all four substudies of this thesis (I-IV).
For the Finnish patients, diagnostic FFPE tumor tissue biopsies from primary orchiectomy 
samples were collected from the local biobanks. Lymphoma diagnoses were re-evaluated by 
experienced hematopathologists to match the latest revised Fourth Edition of the WHO clas-
sification	of	Tumours	of	Haematopoietic	and	Lymphoid	Tissues	[6].	TMA	was	constructed	from	
FFPE tumor samples, and the cores were selected by the hematopathologist. The samples 
were used for analysis in all four original publications of this thesis (substudies I-IV).
Gene	expression	analysis	was	used	for	molecular	immunological	profiling	(substudies	II	
and IV). IHC and multiplex immunohistochemistry (mIHC) were conducted to study the cellular 
immunological	profiles	(substudies	I-IV).	mIHC	was	utilized	in	studying	TIL,	TAM,	and	tumor	
cell immunophenotypes as well as the PD-1–PD-L1 pathway (substudies II-IV).
Lymphoma	stage	was	defined	using	the	Ann	Arbor	classification,	and	COO	was	deter-
mined according to the Hans algorithm (substudies I-IV) [65,96,479].
4.2.1 Immunohistochemistry (I-II)
IHC was conducted on TMA slides according to the manufacturer’s instructions. After depa-
raffinization,	heat-induced	epitope	retrieval	(121°C,	3	minutes),	and	blocking	of	endogenous	
peroxidase, TMA sections were incubated with Abs. A list of all generally validated Abs used 
in substudies I-IV is provided in Table 8. Stainings were completed with Vectastain ABC-HRP 
(Peroxidase) Kit reagents (Vector Laboratories, Burlingame, CA, USA) according to the manu-
facturer’s instructions, and slides were counterstained with hematoxylin.
The samples were scored positive for CD10, Bcl-6, and MUM-1 if 30% or more of the 
tumor cells were stained with the Ab. For Bcl-2, the cutoff level was 50%. In substudy II, 
patients were divided into three subgroups based on Anti-HLA class I ABC Ab, Anti-HLA class 
II DR Ab, and B2M IHC stainings: patients with membranous staining in the majority (>90 %) of 
the	tumor	cells	were	classified	as	highly	positive	(normal).	Patients	with	no	membranous	stain-
ing	were	stratified	as	negative.	The	cases	with	mixed	cytoplasmic	and	membranous	staining	
were	classified	as	moderately	positive.	Highly	positive	and	moderately	positive	groups	were	
merged	when	defining	the	triple-positive	group.
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Table 8. Antibodies and mIHC panels. 
IHC (substudy, I-IV)
I CD79a* CD10* Bcl-2* Bcl-6* MUM-1*
II HLA-ABC HLA-DR B2M
Theme of mIHC (substudy, I-IV) GFP/FITC
(green)
Cy3
(blue)
Cy5
(red)
Cy7
(white)
Panel 
number
T-cells and NK cells (II) CD56 CD31 CD81 CD41 1
Tregs and Th1 cells (III) T-bet CD32 FoxP3 CD42 2
Exhausted CD3+ and CD4+ T-cells (III) CD43 CD32 TIM-3 LAG-31 3
Activated CD8+ T-cells (III) GrB OX40 Ki-67 CD82 4
Exhausted CD8+ T-cells (III) LAG-32 PD-1
+ TIM-3 CD82 5
T-cells (IV) PD-12 CD31 CD81 CD41 6
Macrophages (IV) c-MAF PD-L1 PD-L2 CD68 7
B-cells and macrophages (IV) PD-12 PD-L1 CD163 CD20 8
aAbs: HLA-ABC (clone EMR8-5) Abcam, HLA-DR (clone LN3) Abcam, B2M (clone A0072) Dako, CD56 (clone MRQ-42) Cell Marque 
Rocklin CA, CD31 (clone EP449E) Abcam, CD81 (clone C8/114B) Abcam, CD41 (clone EPR6855) Abcam, T-bet (clone 91109) Abcam, 
CD32 (clone MA5-14482) Thermo, FoxP3 (clone 20034) Abcam, CD42 (clone ab133616), CD43 (clone MA5-12229) Thermo, TIM-3 
(clone 45208) CST, LAG-31 (clone C18692) Lsbio, GrB (clone ab4059) Abcam, OX40 (clone 14-1347-82) Thermo, Ki-67 (clone 
9106-S0) Thermo, CD82 (clone M7103) Dako, LAG-32 (clone 180187) Abcam, PD-11 (clone B12784) LSBio, PD-12 (clone PDCD1) 
LsBio, c-MAF (clone EPR16484) Abcam, PD-L1 (clone E1L3N) Cell Signaling, PD-L2 (polyclonal) Sigma, CD68 (clone KP1) Abcam, 
CD163	(clone	EPR14643)	Abcam,	CD20	(clone	L26)	BioSB;	*Validated	standard	Ab	in	routine	clinical	use;	GFP,	Green	fluorescent	
protein; FITC, Fluorescein isothiocyanate; Cy, Cyanine.
4.2.2 Multiplex immunohistochemistry (II-IV)
mIHC	is	a	technique	combining	fluorescent	and	chromogenic	stainings	with	DAPI	counterstain	
to detect the nucleus, enabling the detection of four different markers in one cell simultane-
ously. The Abs and panels used in mIHC are listed in Table 8.
First,	 TMA	blocks	were	 cut	 in	 3.5	 μm	 sections,	 dried	 overnight,	 and	 stored	 for	 short-
term	use	at	+4°C.	Protein	blocking	and	Ab	incubations	were	performed	in	a	humid	chamber.	
TMA	slides	were	deparaffinized	in	xylene	and	rehydrated	in	graded	ethanol	series	and	H2O. 
Heat-induced epitope retrieval (HIER) was carried out in 10 mM Tris-HCl–1 mM EDTA buffer 
(pH	9)	 in	+99°C	 for	20	min	 (PT	Module,	Thermo	Fisher	Scientific,	Waltham,	MA).	Peroxide	
activity was blocked in 0.9% H2O2 solution for 15 min. Protein block was performed with 10% 
normal goat serum (TBS-NGS) for 15 min. Slides were washed three times with 0.1% Tween-20 
(Thermo	Fisher	Scientific)	diluted	in	10	mM	Tris-HCL	buffered	saline	pH	7.4	(TBS)	after	perox-
ide	block,	Ab	incubations,	and	fluorochrome	reaction.
Primary Abs were diluted in protein blocking solution and incubated for 1 h 45 min. Sec-
ondary anti-mouse or anti-rabbit horseradish peroxidase-conjugated (HRP) Abs (Immunologic, 
Netherlands)	diluted	1:1	with	washing	buffer	were	applied	for	45	min.	Tyramide	signal	amplifi-
cation (TSA) Alexa Fluor 488 (PerkinElmer, Waltham, MA) diluted in TBS was applied for 10 min.
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Primary Abs were denaturated and enzymatic activity of secondary Ab HRP was quenched 
by repeating HIER. After this, peroxide and protein block were repeated, followed by applica-
tion of a different primary Ab, and matching HRP-conjugated secondary Ab diluted 1:3 with 
washing buffer and TSA Alexa Fluor 555 (PerkinElmer). Thereafter, HIER, peroxide block, and 
protein block were again repeated. Subsequently, the slides were incubated with two addi-
tional	primary	Abs	immunized	in	different	species	overnight	in	+4°C.	Next,	AlexaFluor647	and	
AlexaFluor750	fluorochrome-conjugated	secondary	Abs	(Thermo	Fisher	Scientific)	diluted	in	
1:150 and DAPI (Roche) counterstain diluted 1:250 in washing buffer were applied for 45 min. 
Finally,	ProLong	Gold	mountant	(Thermo	Fisher	Scientific)	and	a	coverslip	were	applied	on	the	
slides.
With the aim of minimizing false positive signal from Ab cross-reactions during the mIHC 
procedure, primary Abs selected for mIHC were required to be completely denatured dur-
ing the HIER step between staining rounds. This was assured by examining the denaturation 
properties of all primary Abs by performing an additional HIER step between primary and 
secondary Ab incubation. Abs not denaturing completely were detected with Cy5 and Cy7 
fluorescence	probes,	which	do	not	require	denaturation.
Fluorescent images were established with Axiolmager.Z2 (Zeiss, Germany) microscope 
equipped with a Zeiss Plan-Apochromat 20x objective (NA 0.8, papers II and IV) or EC Plan-Ne-
ofluar	20x	objective	 (NA	0.8,	paper	 III),	CoolCube1	CCD	camera	 (MetaSystems,	Germany),	
PhotoFluor LM-75 (89 North) metal-halide light source, and Zeiss EPLAX VP232-2 power sup-
ply.	DAPI,	FITC,	Cy3,	Cy5,	and	Cy7	filters	with	compatible	LED	light	sources	were	used	and	
exposure	times	for	all	fluorescence	channels	were	optimized	visually	for	fluorescence	imaging.	
Scanned images were acquired and converted to JPEG2000 format (95% quality) for image 
analysis to enable reduction in memory demand.
In	the	image	analysis,	the	quality	of	gray-scale	images	of	each	TMA	spot	was	first	assessed.	
Few images were discarded due to blurred focusing or unsuccessful image registration caused 
mainly by air bubbles in mounting media or shattered tissue, respectively. DAPI-counter-
stained nuclei were segmented with adaptive Otsu thresholding, clumped objects separated 
by intensity patterns, and cells segmented with nuclei contour expansion. Machine-learning 
platform	CellProfiler	2.1.2	and	2.2.0	was	used	for	cell	segmentation,	intensity	measurements	
(upper	quartile	 intensity),	 and	 immune	 cell	 classification	 [480].	 Single-cell	 analysis	 software	
FlowJo v10 (FlowJo LLC.) was used for computing the marker co-localization. The optimal 
gate	coordinates	were	ensured	by	visualizing	matching	cells	with	CellProfiler.
Spots with fewer than 5,000 cells were excluded from the analyses, and data from dupli-
cate spots of the same patient were merged by using the mean value. The proportions of dif-
ferent	immune	cell	subtypes	were	defined	as	either	the	proportion	of	all	cells	(e.g.	CD3+CD4+ 
cells implying the proportion of CD3+CD4+ cells of all the cells in a TMA spot) or the proportion 
of distinct immune cell subtype (e.g. PD-1+CD3+/CD3+ implying the proportion of PD-1+CD3+ 
cells of all CD3+ cells in a TMA spot).
4.2.3 Gene expression analysis (II, IV)
Gene expression analysis was performed using Nanostring nCounter Human PanCancer 
Immunoprofiling	Panel	 (XT-CSO-HIP1-12,	NanoString	Technologies,	Seattle,	WA).	The	 total	
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RNAs were isolated with RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE (Life Technolo-
gies,	Thermo	Fisher	Inc.,	Waltham,	MA).	Two	or	three	20	μm	sections	were	cut	from	the	FFPE	
blocks and processed according to the manufacturer’s instructions. A total of 100 ng of RNA 
was	hybridized	overnight	at	65°C	with	the	Human	PanCancer	Immunoprofiling	Panel	code-
sets	(XT-CSOHIP1-12,	NanoString	Technologies,	Seattle,	WA).	Purification	and	binding	of	the	
hybridized probes to the cartridge were performed on the nCounter Prep Station, followed by 
scanning the cartridge on the nCounter Digital Analyzer (Nanostring Technologies).
The data were analyzed with nSolver 3.0 software (NanoString Technologies). The qual-
ity	of	the	data	was	confirmed	by	using	the	default	QC	settings,	and	normalization	was	done	
using the geNorm algorithm1. The data were log2-transformed for subsequent analyses. For 
hierarchical clustering, the data were z-score-transformed, and clustering was done with the 
JExpress 2012 software2 using Euclidean distance with average linkage. Pathway analysis was 
done with DAVID Bioinformatics Resources 6.83, using genes from the PanCancer Immuno-
profiling	Panel	as	a	background.
4.3 Statistical methods
In	all	the	substudies	included	in	this	thesis,	OS	was	defined	as	time	between	diagnosis	and	
last follow-up or death from any cause, DSS as time between diagnosis and death related to 
lymphoma, and PFS as time between diagnosis and lymphoma progression or death from any 
cause.
Differences in the baseline categorical biological and clinical prognostic factors were 
assessed by using the Chi square test. Mann-Whitney U and Kruskal-Wallis tests were used 
when comparing the frequencies between two or more groups, respectively. The prognostic 
values of different factors were studied with Cox univariate regression analysis. Multivariate 
analyses were performed according to the Cox proportional hazards regression model. Sur-
vival rates were estimated using the Kaplan-Meier method (log-rank test). The correlations 
were tested with Spearman’s rank correlation. The potential bias due to duration of follow-up 
was assessed by Schoenfeld residual. Hierarchical clustering was conducted with JExpress 
2012 Software using Euclidean distance with average linkage [481]. Pathway analysis was done 
with	DAVID	Bioinformatics	Resources	6.8	using	genes	from	the	PanCancer		Immunoprofiling	
Panel as a background [482,483].
Statistical analyses of all the substudies in this thesis were performed using IBM SPSS 
version 24.0 (IBM, Armonk, NY). Probability values below 0.05 were considered statistically 
significant.	All	comparisons	and	all	comparative	tests	were	two-tailed.
4.4 Ethical considerations
This	study	is	a	retrospective	analysis	and	did	not	influence	the	treatment	of	patients	included	
in this study. The study protocol and sampling were approved by the Institutional Review 
Boards, Ethics Committees, and Finnish National Supervisory Authority for Welfare and Health 
(Valvira, license number 9505/06.01.03.01/2013).
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5 Results
5.1 Patient characteristics
5.1.1 Nordic collaborative study (I)
We found altogether 235 patients with T-DLBCL and clinical data available. Among these 
patients, median age at diagnosis was 71 years (range 37–93 years) and all but two patients 
had undergone orchiectomy. Of the patients, 40% (n=95) had an isolated lymphoma involve-
ment of one or both testes and were considered as stage I disease; 62% of the cases (n=146) 
had a limited stage disease (stage I-II) and were considered as primary T-DLBCLs [96]. Lym-
phoma involvement of the contralateral testis was detected among 11% (n=8) of the Finnish 
patients (n=75) but this information was not recorded for the Danish patients.
For further analyses, we selected the patients who, in addition to undergoing orchiec-
tomy, had been treated with active systemic (immune-)chemotherapy ((R-)CHOP or (R-)CHOP 
-like regimen) with curative intent. Patients with concurrent CNS lymphoma involvement at 
diagnosis (n=7) and two patients with no information available on the cause of death were 
excluded, resulting in a total of 189 patients with median age at diagnosis of 69 years (range 
37–88 years) for further analysis. Less than half of these 189 patients (40%, n=76) had been 
treated with IV CNS-targeted chemotherapy and 66% (n=124) had advanced stage T-DLBCL. 
Of the 189 patients, 63% (n=120) had been treated with rituximab whereas 37% (n=69) had 
been treated in the pre-rituximab era. Baseline patient characteristics of the 189 patients, 
distributed according to IV CNS-targeted therapy, are summarized in Table 1, substudy I, 
whereas Table S1, substudy I, distributes the patients according to primary T-DLBCL and 
advanced stage T-DLBCL [96].
Altogether	91	Finnish	patients	with	T-DLBCL	were	identified.	Among	these	patients,	pri-
mary diagnostic T-DLBCL tissue was available for further analysis from 79 of the cases. For all 
79	cases,	the	diagnosis	of	T-DLBCL	was	confirmed	according	to	the	revised	Fourth	Edition	of	
the	WHO	classification	of	Tumours	of	Haematopoietic	and	Lymphoid	Tissues	[6].	Seventy-four	
of these patients were included in the analysis of biological risk factors in the Nordic collabora-
tive study (substudy I). Of these 74 cases, 81% (n=60) had been treated with a curative intent, 
and 76% (n=56) represented non-GCB phenotype DLBCL based on the Hans algorithm [65]. 
Bcl-2 and Bcl-6 IHC results were available for 61 T-DLBCL patients, with 77% (n=47) positive 
with Bcl-2 and 38% (n=23) positive with Bcl-6. Data on c-Myc IHC was available for 38 T-DLBCL 
patients with only one case scored as positive.
5.1.2 Translational studies (II-IV)
All 79 T-DLBCL patients with tumor tissue available were included in the TIL immunophenotype 
analyses (substudy III), whereas for the analysis on TAMs, TILs, and the PD-1–PD-L1 pathway 
(substudy IV), few images were discarded due to blurred focusing or unsuccessful image regis-
tration, as described earlier in section 4.2.2, resulting in a total of 74 patients. Sixty patients had 
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been treated with anthracycline-based (immune-)chemotherapy with curative intent and were 
included	in	the	gene	expression	profiling	and	T-/NK	cell	analysis	(substudies	II,	IV).
The majority of the 60 T-DLBCL patients treated with anthracycline-based (immune-)
chemotherapy with curative intent were over 60 years of age at diagnosis, had a limited stage 
disease, low IPI score, and had received rituximab and IV CNS-targeted chemotherapy as part 
of their lymphoma treatment. The contralateral testis had been treated (either surgically or by 
irradiation) only in a minority of the patients. The majority of the cases represented non-GCB 
phenotype DLBCL. The baseline patient characteristics of these 60 patients are summarized 
in Table 1, substudy II.
For comparison, we used data of 96 patients with primary DLBCL from the CGCI cohort 
(substudy II) [478]. The majority of the patients with primary DLBCL were over 60 years of 
age at diagnosis but, unlike the 60 patients with T-DLBCL, only a minority of the patients with 
primary DLBCL had a limited stage disease and low IPI score (Table 1, substudy II). A vast 
majority of the primary DLBCL patients had been treated with a rituximab-containing regimen, 
and slightly less than half of the cases represented non-CGB phenotype DLBCL. Additionally, 
one third of the patients were women. The baseline patient characteristics of the 96 primary 
DLBCL patients are summarized in Table 1, substudy II.
The largest T-DLBCL cohort among the translational studies was the cohort of 79 patients 
in the TIL immunophenotype analysis (substudy III) with median age at diagnosis being 70 years 
(range	37–92	years).	The	baseline	patient	characteristics	did	not	significantly	differ	according	
to stage, IPI score, or COO from those described earlier among the 60 patients treated with 
curative intent (Table 1, substudy II; Table 1, substudy III). The proportion of patients that had 
been treated with rituximab and/or IV CNS-targeted chemotherapy was, however, slightly 
smaller in this larger patient cohort (Table 1, substudy III).
The baseline patient characteristics of the 74 patients included in the analyses of TAMs, 
TILs, and the PD-1–PD-L1 pathway (substudy IV) were comparable with those of all 79 patients 
with tumor tissue available (substudy III) and are listed in Table 1, substudy IV, distributed 
according to the content of PD-L1+ TAMs.
5.2 Treatment modalities
The use of different treatment modalities was analyzed in the Nordic collaborative study with 
189 T-DLBCL patients (substudy I), all of them treated with anthracycline-based (R-)CHOP or 
(R-)CHOP-like regimen. As described earlier in section 5.1.1, the majority of these patients 
had received rituximab, whereas only a minority of them were treated with IV CNS-targeted 
chemotherapy (HD-Mtx or HD-Ara-C). IT CNS-targeted chemotherapy was given to 33% of 
the patients (n=63). All patients had undergone orchiectomy, and the contralateral testis was 
treated in 47% of the patients (n=88), with surgery in 13 and with irradiation in 75 patients.
The use of IV CNS-targeted chemotherapy was as common in the rituximab era as 
before the introduction of rituximab (43% vs. 36%, p=0.443, respectively). Instead, patients 
receiving	IV	CNS-targeted	chemotherapy	were	significantly	younger	than	the	ones	treated	with	
no CNS-targeted chemotherapy or with IT CNS-targeted chemotherapy only (68% vs. 39% of 
the patients 70 years or younger at diagnosis, p<0.001, respectively, Table 1, substudy I). 
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Other baseline patient characteristics such as performance status, stage, IPI score, or COO 
did	not	significantly	differ	between	patients	receiving	IV	CNS-targeted	chemotherapy	or	not.
Treatment of the contralateral testis and the use of IT only CNS-targeted chemotherapy 
were more common in the rituximab era (treatment of the contralateral testis or not, 53% 
vs. 36%, p=0.035; and IT only CNS-targeted chemotherapy or not, 42% vs. 19%, p=0.014, 
after and before the introduction of rituximab, respectively) and in Denmark than in Finland 
(treatment of the contralateral testis or not, 53% vs. 33%, p=0.002; and IT only CNS-targeted 
chemotherapy or not, 37% vs. 7%, p<0.001, in Denmark vs. in Finland, respectively). Anal-
ogously, the contralateral testis was more often treated among patients who had received 
IT CNS-targeted chemotherapy (treatment of the contralateral testis in 65% vs. 37% of the 
patients receiving IT CNS-targeted therapy or not, p<0.001, respectively). Only 8% of the 
patients (n=16) were treated with both IT and IV CNS-targeted chemotherapy, more com-
monly in combination with rituximab (13 vs. 3 patients, treated with or without rituximab, 
respectively).
5.3 The molecular immunological profiles
The	molecular	immunological	profiles	were	studied	by	analyzing	the	gene	expression	levels	
of 730 immune-associated genes and 40 housekeeping genes from FFPE primary diagnostic 
lymphoma tissue of 60 T-DLBCL patients with Nanostring nCounter Human PanCancer Immu-
noprofiling	Panel.	The	 results	were	compared	with	corresponding	data	of	96	patients	with	
primary DLBCL.
5.3.1 Molecular immunological profiles in T-DLBCL (II)
Based	on	an	unsupervised	hierarchical	clustering,	we	identified	three	gene	signatures	differen-
tially expressed between T-DLBCL patients, Figure 1, substudy II. The largest cluster consisted 
of 121 genes forming a gene signature clearly separating the patients into three subgroups 
with different expression levels (low, intermediate, and high; Figures 2a and S1a, substudy II). 
The signature was named “T-lymphocyte signature” based on the genes in the signature that 
were found to be enriched for T-cell and NK cell markers and signaling (e.g. CD3D/E/G, CD4, 
and CD8A/B). A list of all 121 genes in the signature is presented in Table S1, substudy II, and 
a list of the pathways enriched among these genes is shown in Table 2, substudy II. There were 
no	significant	differences	 in	 the	baseline	patient	characteristics	 including	age	at	diagnosis,	
stage, IPI score, COO, and treatments between the patients with higher and low expression 
of the T-lymphocyte signature genes (Table S5, substudy II).
Two smaller signatures were named “Cytokine signature I” and “Cytokine signature 
II” based on the 44 genes enriched for cytokines and 25 genes enriched for cytokines and 
cytokine receptors, respectively. The genes in Cytokine signatures I and II are listed in Tables 
S2 and S3, substudy II. The absolute expression levels of Cytokine signature II genes were low, 
but patients could be divided into two subgroups with higher and lower expression levels and 
there	were	no	significant	differences	in	the	baseline	patient	characteristics	between	these	two	
subgroups.
48 TESTICULAR DIFFUSE LARGE B-CELL LYMPHOMA; PROGNOSTIC CLINICAL, MOLECULAR, AND IMMUNOLOGICAL FACTORS
We also analyzed the expression levels of macrophage genes CD68, CD163, and MAF; 
B-cell gene MS4A1 (CD20); and immune checkpoint molecules coding genes CD274 (PD-L1), 
PDCD1LG2 (PD-L2), and PDCD1 (PD-1). We observed a strong correlation between the expres-
sion levels of CD68 with the expression levels of CD274 (rs=0.654, p<0.001), PDCD1LG2 
(rs=0.636, p<0.001), CD163 (rs=0.602, p<0.001), and MAF (rs=0.425, p=0.001), and slightly 
less strong correlation with the expression level of PDCD1 (rs=0.300, p=0.020). There was no 
correlation between the expression of CD68 and MS4A1.
5.3.2 Molecular immunological profiles in primary DLBCL (II)
RNA-sequencing data from patients with primary DLBCL was used for comparison. Performing 
a hierarchical clustering of the gene expressions levels of the T-lymphocyte signature genes, 
we found a subgroup of patients with low gene expression levels (Figures 2e and S1c, sub-
study II). When comparing the primary DLBCL patients with high and low expression levels of 
the	T-lymphocyte	signature	genes,	there	were	no	significant	differences	in	the	baseline	patient	
characteristics. The baseline patient characteristics of the T-lymphocyte signature patient 
groups in the primary DLBCL cohort are summarized in Table S5, substudy II. The expression 
levels	of	Cytokine	 signature	 I	 and	 II	genes	did	not	 significantly	differ	 among	patients	with	
primary DLBCL.
5.4 The cellular immunological profiles
IHC and mIHC were utilized in examining NK cells and the expression of HLA class I and II 
molecules (substudy II); TIL immunophenotypes (substudy III); and TAMs, TILs, and the PD-1–
PD-L1 pathway (substudy IV) from FFPE tumor tissue samples of patients with T-DLBCL.The 
expression of HLA molecules I and II as well as B2M, a component of HLA I, was determined 
in order to study the escape of the tumor cells from immunosurveillance. Markers CD3 and 
CD8 were used to detect all TILs and CTLs, respectively; CD4 in combination with FoxP3 and 
T-bet was used to identify Tregs and Th1 cells, respectively. CD68 was used to detect all TAMs, 
whereas other macrophage markers (CD163 and c-MAF) were used to identify M2-polarized 
TAMs. CD20 was used to identify lymphoma cells, and CD56 to detect NK cells. Subpopu-
lations	of	TAMs	and	TILs	were	defined	by	the	presence	or	absence	of	PD-1,	PD-L1,	PD-L3,	
LAG-3, TIM-3, OX40, GrB, and Ki-67. All the panels and Abs are described in more detail in 
Table 8, section 4.2.1.
5.4.1 TIL immunophenotypes (III, IV)
To	get	a	better	overview	of	the	results	on	specific	TIL	immunophenotypes,	we	performed	an	
unsupervised hierarchical clustering of the data studied in substudy III and could see that the 
expression of all the studied markers combined clearly separated the patients into subgroups 
with higher and lower expression (Cluster 1, named “T-cell cluster”, Figure 1a, substudy III). 
Analyzing all the exhaustion markers studied in substudy III, the patients could be further 
divided into subgroups with higher and lower expression of all the exhaustion markers com-
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bined (Cluster 2, named “Exhausted phenotype cluster”, Figure 1b, substudy III). Additional 
smaller clusters (named “Cytotoxic activity cluster”, “Proliferative cells cluster”, and “Treg clus-
ter”)	could	also	be	observed	and	are	shown	in	Figure	S1,	substudy	III.	There	were	no	signifi-
cant differences between the high and low subgroups of the T-cell and Exhausted phenotype 
clusters according to the known clinical and biological risk factors (Table S3, substudy III).
Altogether, great variation in the content of distinct TIL subtypes and their immunophe-
notypes could be seen between the patients (Figures 2a-d, substudy III). In addition to Ki-67+ 
CTLs, the most common immunophenotypes were the exhausted TILs. Clearly the most prom-
inent exhaustion marker among both CD4+ TILs and CTLs was PD-1, whereas the content of 
LAG-3+TIM-3+ double positive TILs was fairly low. The most prominent CD4+ TIL subtype was 
FoxP3+ Treg while the proportions of T-bet
+ Th1 cells were considerably low. A small subpopu-
lation of CD4+ TILs was FoxP3+T-bet+ double positive.
We	observed	altogether	higher	proportions	of	TILs	and	more	specifically,	a	higher	con-
tent of activated CTLs among patients with non-GCB phenotype, whereas higher proportions 
of CD4+ TILs associated with a limited stage disease. The contents of activated and exhausted 
CTLs were lower among patients with advanced stage disease and B-symptoms. Addition-
ally, some variation in the proportions of distinct TIL phenotypes could be seen according 
to	 the	patients’	 age	 at	 diagnosis.	All	 significant	 associations	of	 different	 TIL	 subtypes	 and	
immunophenotypes with the known clinical and biological risk factors are shown in Figure 3, 
substudy III.
5.4.2 HLA class I and II expression (II)
We observed that only a minority of the T-DLBCL patients showed highly positive membra-
nous staining with HLA-ABC (HLA class I), HLA-DR (HLA class II), and B2M (28%, 17%, and 
13%, respectively).
5.4.3 TAMs, NK cells, and the PD-1–PD-L1 pathway (II, IV)
Correspondingly to TILs, the content of other studied immune cell subtypes varied greatly 
between the patients (Figure 1, substudy IV). We observed that not only a large proportion 
of TAMs but also a major subpopulation of the tumor cells expressed PD-L1, and about half 
of the TILs expressed PD-1 (Figure 1, substudy IV; see also Table 11 in section 5.4.4). Further-
more, the content of PD-1+	TILs	correlated	significantly	with	the	content	of	PD-L1+ TAMs (Table 
S2, substudy IV). The relative proportions of CD3-CD56+ NK cells were very low (median 0.3%, 
range 0.0%–57.2%) as was the overall expression of PD-L2 (median 0.1%, range 0.0%–6.4%).
Significantly	higher	content	of	PD-L1+ TAMs was observed among patients with a limited 
stage	disease	whereas	no	other	significant	differences	in	the	known	clinical	and	biological	risk	
factors could be found between patients with different proportions of PD-L1+ TAMs (Table 1, 
substudy IV).
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5.4.4 A summary of the cellular immunological profiles (II-IV)
There was a high agreement with the results of the proportions of distinct immune cell sub-
types according to different panels, and for a summary of the analyses in this thesis, the data 
of different panels were merged by using the mean value of the panels (e.g. the mean propor-
tion of CD3+ cells based on panels 1, 2, 3, and 6) (M.P. et al. unpublished results). The correla-
tions between different panels are listed in Table 9 (M.P. et al. unpublished results).
Table 9. Correlation of the TIL subtypes based on different mIHC panels. 
mIHC rsa p-value
CD3+ panel 1 vs. panel 2 0.919 <0.001
CD3+ panel 1 vs. panel 3 0.932 <0.001
CD3+ panel 1 vs. panel 6 0.972 <0.001
CD3+ panel 2 vs. panel 3 0.976 <0.001
CD3+ panel 2 vs. panel 6 0.877 <0.001
CD3+ panel 3 vs. panel 6 0.882 <0.001
CD3+CD4+ panel 1 vs. panel 2 0.885 <0.001
CD3+CD4+ panel 1 vs. panel 3 0.855 <0.001
CD3+CD4+ panel 1 vs. panel 6 0.982 <0.001
CD3+CD4+ panel 2 vs. panel 3 0.914 <0.001
CD3+CD4+ panel 2 vs. panel 6 0.865 <0.001
CD3+CD4+ panel 3 vs. panel 6 0.801 <0.001
CD8+ panel 4 vs. panel 5 0.893 <0.001
CD3+CD8+ panel 1 vs. panel 6 0.926 <0.001
CD8+ panel 4 vs. CD3+8+ panel 1 0.861 <0.001
CD8+ panel 5 vs. CD3+8+ panel 1 0.943 <0.001
CD8+ panel 4 vs. CD3+8+ panel 6 0.732 <0.001
CD8+ panel 5 vs. CD3+8+ panel 6 0.828 <0.001
PD-1+ panel 5 vs. panel 8 0.651 <0.001
PD-L1+ panel 7 vs. panel 8 0.946 <0.001
PD-1+CD8+/CD8+ panel 5 vs. PD-1+CD3+CD8+/CD8+ panel 6 0.554 <0.001
LAG-3+ panel 3 vs. panel 5 0.533 <0.001
TIM-3+ panel 3 vs. panel 5 0.942 <0.001
aSpearman rho. M.P. et al. unpublished results.
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Additionally, as a proof of concept, the expressions of distinct immune cell phenotype markers 
at the protein level were shown to correlate with the corresponding gene expressions and are 
listed in Table 10 (M.P. et al. unpublished results).
Table 10. Correlation of the gene expression levels with the corresponding expression 
on protein level. 
mIHC vs. gene expression level rsa p-value
mean CD3+ (panels 1, 2, 3, and 6) vs. CD3D 0.773 <0.001
mean CD3+ (panels 1, 2, 3, and 6) vs. CD3E 0.724 <0.001
mean CD3+ (panels 1, 2, 3, and 6) vs. CD3G 0.720 <0.001
mean CD4+ (panels 2 and 3) vs. CD4 0.497 <0.001
mean CD8+ (panels 4 and 5) vs. CD8A 0.705 <0.001
mean CD8+ (panels 4 and 5) vs. CD8B 0.674 <0.001
CD20+ vs. MS4A1 0.817 <0.001
CD68+ vs. CD68 0.643 <0.001
mean PD-1+ (panels 5 and 8) vs. PDCD1 0.701 <0.001
mean PD-L1+ (panels 7 and 8) vs. CD274 0.747 <0.001
mean LAG-3+ (panels 3 and 5) vs. LAG3 0.533 <0.001
mean TIM-3+ (panel 3 and 5) vs. HAVCR2 0.762 <0.001
FoxP3+ vs. FOXP3 0.656 <0.001
T-bet+ vs. TBX21 0.212 0.108
GrB+ vs. GZMB 0.659 <0.001
aSpearman rho; p-val. M.P. et al. unpublished results.
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A summary of the median proportions of distinct immune cell subtypes in the TME studied 
in substudies II-IV is shown in Table 11 (M.P. et al. unpublished results).
Table 11. Median proportions of distinct immune cell subtypes in the TME.
mIHC median, % (range)
CD3+ T-cells and PD-1
mean CD3+ (panels 1, 2, 3, and 6) 20.7 (0.0-69.5)
mean PD-1+ (panels 5 and 8) 6.9 (0.0-53.5)
FoxP3+CD3+/CD3+ 2.7 (0.2-16.4)
T-bet+CD3+/CD3+ 0.1 (0.0-2.3)
LAG-3+CD3+/CD3+ 0.3 (0.0-7.0)
TIM-3+CD3+/CD3+ 5.2 (0.5-36.2)
FoxP3+T-bet+CD3+/CD3+ 0.0 (0.0-2.0)
LAG-3+TIM-3+CD3+/CD3+ 0.2 (0.0-5.1)
CD3+CD4+ T-cells
mean CD3+CD4+ (panels 1, 2, 3, and 6) 9.5 (0.0-60.0)
PD-1+CD3+CD4+ 12.3 (0.3-65.9)
FoxP3+CD3+CD4+/CD3+CD4+ 10.8 (0.0-50.3)
T-bet+CD3+CD4+/CD3+CD4+ 0.0 (0.0-6.5)
LAG-3+CD3+CD4+/CD3+CD4+ 0.2 (0.0-8.6)
TIM-3+CD3+CD4+/CD3+CD4+ 6.5 (0.1-36.2)
PD-1+CD3+CD4+/CD3+CD4+ 58.5 (3.8-100.0)
FoxP3+T-bet+CD3+CD4+/CD3+CD4+ 0.0 (0.0-6.1)
FoxP3-T-bet+CD3+CD4+/CD3+CD4+ 2.2 (0.0-84.7)
LAG-3+TIM-3+CD3+CD4+/CD3+CD4+ 0.1 (0.0-5.0)
CD8+ T-cells
mean CD3+CD8+ (panels 1 and 6) 17.3 (0.0-66.0)
PD-1+CD3+CD8+ 13.9 (0.3-67.2)
OX40+CD8+/CD8+ 0.1 (0.0-1.5)
GrB+CD8+/CD8+ 2.5 (0.0-25.3)
Ki-67+CD8+/CD8+ 22.2 (4.7-85.6)
LAG-3+CD8+/CD8+ 1.1 (0.0-10.1)
TIM-3+CD8+/CD8+ 3.6 (0.5-36.2)
PD-1+CD3+CD8+/CD3+CD8+ 64.4 (4.1-100.0)
OX40+GrB+CD8+/CD8+ 0.0 (0.0-0.9)
GrB+Ki-67+CD8+/CD8+ 0.3 (0.0-5.8)
OX40+Ki-67+CD8+/CD8+ 0.0 (0.0-0.44)
LAG-3+TIM-3+CD8+/CD8+ 0.3 (0.0-6.6)
LAG-3+PD-1+CD8+/CD8+ 0.1 (0.0-5.2)
TIM-3+PD-1+CD8+/CD8+ 0.2 (0.0-5.4)
Macrophages and PD-L1
CD68+ 23.4 (3.4-81.0)
mean PD-L1+ (panels 7 and 8) 22.5 (0.1-99.8)
PD-L1+CD68+ 9.4 (0.0-74.4)
PD-L1+CD68+ 10.5 (0.1-51.6)
PD-L1+CD68+ 5.0 (0.0-90.5)
PD-L1+CD68+/CD68+ 41.4 (0.1-99.4)
c-MAF+CD68+/CD68+ 5.6 (0.0-35.4)
PD-L1+c-MAF+CD68+/CD68+ 2.4 (0.0-21.7)
Lymphoma cells
CD20+ 87.2 (1.4-99.8)
PD-L1+CD20+ 19.7 (0.1-98.3)
PD-L1+CD20+/CD20+ 34.2 (0.1-100)
M.P. et al. unpublished results.
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5.5 Survival analyses
The effect of clinical and biological risk factors as well as different treatment modalities on the 
survival of T-DLBCL patients was analyzed in the Nordic collaborative study (substudy I). The 
association	of	molecular	immunological	profiles	as	well	as	cellular	immunological	profiles	with	
the survival of T-DLBCL patients was analyzed in the translational studies using gene expres-
sion	profiling,	IHC,	and	mIHC	(substudies	II-IV).
5.5.1 Nordic collaborative study (I)
Among the 189 Nordic T-DLBCL patients that had been treated with a curative intent, the 
median follow-up was 80 months (range 7–192 months). The cause of death was reported 
in 79% (n=81) of the 102 registered deaths, with lymphoma being the most common cause 
(56%, n=57). Major non-lymphoma-related causes of death were other malignancies (10%, 
n=10),	cardiovascular	failure	(7%,	n=7),	and	infections	(3%,	n=3).	The	five-year	OS,	DSS,	and	
PFS rates were 60%, 71%, and 52%, respectively. Age of 70 years or above at diagnosis, 
advanced stage disease, and high IPI score (IPI 3-5), all known risk factors in DLBCL, associ-
ated with worse survival (Figures S1d-l and Table 2, substudy I). When all the factors that had 
a	significant	impact	on	the	patient	outcome	were	included	in	a	multivariate	analysis,	all	other	
risk factors included in the IPI score except stage remained as independent risk factors for OS 
and PFS (Table 3, substudy I).
Only	6%	of	the	patients	 (n=12)	experienced	CNS	relapse	as	their	first	recurrence,	 lym-
phoma	being	the	cause	of	death	for	all	but	one	of	them.	The	risk	of	CNS	relapse	was	signifi-
cantly higher among patients with advanced stage disease, higher IPI score, and higher num-
ber of extranodal sites of primary lymphoma involvement (Table 2, substudy I). Information 
on primary adrenal gland or kidney involvement was available for 87% of the patients (n=164) 
and did not associate with increased risk of CNS relapse (HR 1.507, 95% CI 0.196–11.610, 
p=0.694) or add to the predictive impact of the IPI score. Additional 6 cases of CNS progres-
sion at later relapses were observed, with lymphoma being the cause of death for all of these 
patients.
5.5.1.1 Different treatment modalities
In univariate analyses, IV CNS-targeted chemotherapy as well as treatment of the contralat-
eral	testis	were	shown	to	have	significant	association	with	better	survival	of	T-DLBCL	patients	
(Figures 1d-f and 1j-l and Table 2, substudy I). Analyzed together in multivariate analysis with 
age, stage, LHD, the number of extranodal sites involved at diagnosis, and performance sta-
tus, both IV CNS-targeted chemotherapy and treatment of the contralateral testis remained 
as independent prognostic factors for OS, DSS, and PFS (Table 3, substudy I). The difference 
on survival according to whether the patients had received IV CNS-targeted chemotherapy 
or	not	remained	significant	also	when	adjusted	for	age	(<	or	≥	70	years	at	diagnosis)	and	was	
especially	significant	among	elderly	patients	(five-year	OS,	DSS,	and	PFS	rates	81%	vs.	36%,	
87%	vs.	57%,	and	66%	vs.	30%,	for	patients	≥70	years	at	diagnosis	treated	with	or	without	IV	
CNS-targeted	chemotherapy,	respectively).	The	addition	of	rituximab	significantly	improved	
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DSS	among	chemotherapy-treated	patients	with	high	IPI	score	(five-year	DSS	44%	vs.	14%,	
immunochemotherapy-treated (n=39) vs. chemotherapy-treated (n=14) patients with IPI score 
3–5,	respectively,	p=0.019).	There	was	no	significant	association	with	survival	with	the	use	of	
IT	CNS-targeted	chemotherapy.	The	number	of	CNS	relapses	as	first	recurrence	of	lymphoma	
was altogether low in our patient material (6%), and no association to survival with different 
treatment modalities could be shown.
5.5.1.2 COO and other biological risk factors
Non-GCB	phenotype	had	a	significant	association	to	inferior	survival	with	5-year	PFS	of	53%	
vs. 87%, p=0.05, for the non-GCB vs. GCB phenotypes, respectively. We could also observe 
a trend towards worse prognosis among cases with Bcl-2 positivity (5-year OS 60% vs. 83%, 
p=0.118; 5-year DSS 73% vs. 90%, p=0.105; 5-year PFS 57% vs. 76%, p=0.112, for Bcl-2 
positive vs. Bcl-2 negative cases, respectively). Bcl-6 positivity had no association with patient 
survival, whereas with only one c-Myc positive case, no analyses on its possible impact on 
survival could be conducted.
5.5.2 Translational studies (II-IV)
The	effect	of	molecular	immunological	profiles	on	the	survival	of	T-DLBCL	patients	was	ana-
lyzed and compared with the corresponding data of primary DLBCL patients (substudy II). 
The association of TIL and TAM subtypes and their immunophenotypes with the survival of 
T-DLBCL patients was also studied (substudies III-IV, and IV, respectively). Additionally, the 
association of HLA class I and II expression with the survival of T-DLBCL patients was analyzed 
(substudy II). Among the largest patient population of these translational studies (n=79, sub-
study III) we observed altogether 38 deaths, 27 lymphoma deaths, and 42 lymphoma progres-
sions during the median follow-up of 46 months (range 0–120 months). Correspondingly, the 
five-year	OS,	DSS,	and	PFS	rates	were	54%,	60%,	and	46%,	respectively.	
5.5.2.1 T-cell signature and Cytokine signatures (II)
Patients	with	 low	 (n=12)	 expression	 of	 the	 T-lymphocyte	 signature	 genes	 had	 significantly	
shorter OS, DSS, and PFS than patients with intermediate (n=32) and high (n=16) gene expres-
sion levels (log-rank p=0.009, p=0.003, and p=0.041, respectively). The adverse prognostic 
impact	 of	 the	 low	expression	of	 the	 T-lymphocyte	 signature	genes	 remained	 significant	 in	
multivariate analyses with IPI and was especially evident among patients treated with ritux-
imab (Figures 2c-d and S2b and Table S4, substudy II). In univariate analyses with continu-
ous variables, 72 of the 121 genes in the T-lymphocyte signature, e.g. T-cell surface markers 
CD3D/E/G, CD4, and CD8A/B,	had	a	significant	association	with	survival.	
Patients	 with	 higher	 expression	 of	 the	 Cytokine	 signature	 II	 genes	 had	 significantly	
shorter	five-year	PFS	than	patients	with	lower	or	no	expression	of	the	signature	genes	(36%	
vs.	66%,	p=0.005),	and	the	difference	also	remained	significant	in	multivariate	analysis	with	
IPI (HR=3.393, CI95=1.531–7.521, p=0.003). No association with survival was found with the 
expression of the Cytokine I signature genes.
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Primary DLBCL patients with low expression of the T-lymphocyte signature genes had 
significantly	shorter	survival	than	patients	with	higher	expression	(PFS	p=0.007,	OS	p=0.034,	
	Figure	2f,	substudy	II),	and	the	association	with	PFS	remained	significant	in	multivariate	analysis	
with IPI (HR=2.560, CI95=1.151–5.695, p=0.021). No association with survival was observed 
with the expression levels of Cytokine signature I and II genes among patients with primary 
DLBCL.
5.5.2.2 TIL content and immunophenotypes, HLA class I and II expression 
(II-IV)
Higher content of CD3+ TILs in general, CD4+ TILs, and CTLs translated into better survival 
of T-DLBCL patients when analyzed in univariate analysis with continuous variables (Figure S5 
and Table 3, substudy II; see also Figures 10 and 11 in section 5.5.2.4). The favorable prog-
nostic	 impact	of	high	TIL	content	remained	significant	 in	multivariate	analyses	with	IPI,	and	
consistent	with	the	findings	on	the	gene	expression	level,	the	association	of	high	proportions	
of CD3+CD4+ and CD3+CD8+ lymphocytes with longer survival was especially evident among 
patients treated with rituximab (Figure S6 and Table 3, substudy II; see also Table 12 in section 
5.5.2.4). 
Among patients with T-DLBCL, the expression of HLA	 class	 I	 and	 II	genes	was	 signifi-
cantly lower within patients in the low T-lymphocyte signature subgroup and worse prognosis 
(p<0.05 for both, Figure S7a, substudy II), and the same was seen among patients with primary 
DLBCL (Figure S7b, substudy II). No association with survival was seen with the content of 
CD56+ cells.
Analyzing all the studied TIL markers combined in substudy III, we observed that higher 
expression of the T-cell cluster markers translated into better survival of T-DLBCL patients 
(group A, Cluster 1, Figures 1a and 4a-c, substudy III). The favorable prognostic impact 
remained	 significant	 also	 in	multivariate	 analysis	 with	 IPI	 (see	 Table	 12	 in	 section	 5.5.2.4).	
Unexpectedly, patients with higher expression of the Exhausted phenotype cluster markers 
also tended to have longer survival (group C, Cluster 2, Figures 1b and 4d-f, substudy III), 
although the difference did not remain as an independent prognostic factor in multivariate 
analysis with IPI (see Table 12 in section 5.5.2.4).
The possible association of distinct TIL subtypes and their immunophenotypes with the 
survival of T-DLBCL patients was analyzed using univariate analysis with continuous variables 
(Figure 5, substudy III; see also Figures 10 and 11 in section 5.5.2.4). Patients with overall 
higher content of PD-1+CD3+CD4+ TILs and PD-1+CD3+CD8+	CTLs	had	significantly	longer	sur-
vival, whereas other distinct TIL immunophenotypes could not be associated with better prog-
nosis (Figure 2b-c, substudy IV; see also Figures 10 and 11 in section 5.5.2.4). The prognostic 
value of PD-1+	TILs	remained	significant	in	multivariate	analysis	with	IPI	and	among	patients	
treated with rituximab (Figures S2b-c and Table 4, substudy IV; see also Table 12 in section 
5.5.2.4). Despite the overall favorable prognostic impact of high TIL content and the gener-
ally low proportions of T-bet+ TILs, higher proportions of T-bet+	TILs	correlated	significantly	
with adverse patient outcome (Figures 5 and 6a-c, substudy III). Furthermore, the content of 
FoxP3+T-bet+	double	positive	TILs	was	shown	to	be	a	significant	adverse	prognostic	 factor,	
remaining	independent	in	multivariate	analysis	with	IPI,	and	significant	among	patients	treated	
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with rituximab (OS, HR=1.778, CI95=1.128–2.803, p=0.013) (Figures 5 and 6d-f and Table 2, 
substudy III; see also Table 12 in section 5.5.2.4). Interestingly, the proportion of FoxP3-T-bet+ 
TILs did not have an association with survival (see Figures 10 and 11 in section 5.5.2.4).
5.5.2.3 PD-L1+ TAM content (IV)
In univariate analyses with continuous variables, higher content of PD-L1+ cells, higher pro-
portion of PD-L1+CD68+ TAMs from all cells, and higher proportion of PD-L1+CD68+ TAMs 
from all TAMs (PD-L1+CD68+/CD68+)	had	a	significant	association	with	longer	survival	of	T-DL-
BCL patients (Figure 2a and Table 3, substudy IV). The association of PD-L1+CD68+ content 
with survival remained as an independent prognostic factor in multivariate analysis with IPI 
and was also evident among patients treated with rituximab (Figure S2a and Table 4, sub-
study IV). No association with survival was seen with the content of PD-L1+CD68- cells or 
PD-L1+c-MAF+CD68+ TAMs.
5.5.2.4 A summary of the survival analysis of the translational studies (II-IV)
A summary of the association of different clusters as well as distinct TIL subtypes, their immu-
nophenotypes, and PD-1+ cells with the OS and DSS of T-DLBCL patients is shown in Figures 
8-9 and Figures 10-11, respectively (M.P. et al. unpublished results). A summary of the associ-
ation of TAMs, lymphoma cells, and PD-L1+ cells with the OS and DSS of T-DLBCL patients is 
shown in Figures 12-13 (M.P. et al. unpublished results). A summary of the multivariate analysis 
of the different signatures and the distinct immune cell subtypes with IPI is shown in Table 12 
(M.P. et al. unpublished results).
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Figure 9. The association of different clusters with DSS of T-DLBCL patients. A forest plot 
with univariate analysis showing the association of higher expression of T-lymphocyte signa-
ture	genes	and	T-cell	cluster	markers	with	significantly	longer	DSS	of	T-DBCL	patients.	
M.P. et al. unpublished results.
Figure 8. The association of different clusters with OS of T-DLBCL patients. A forest plot 
with univariate analysis showing the association of higher expression of T-lymphocyte signa-
ture	genes	and	T-cell	cluster	markers	with	significantly	longer	OS	of	T-DBCL	patients. 
M.P. et al. unpublished results.
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Figure 10. The association of distinct TIL subtypes, their immunophenotypes, and PD-1+ 
cells with OS of T-DLBCL patients. A forest plot with univariate analysis using continuous 
variables showing the association of higher proportion of CD3+ TILs in general, CD4+ TILs, 
CD8+ CTLs, PD-1+ CD4+ TILs as well as PD-1+ CTLs with longer OS of T-DLBCL patients. Higher 
proportion of T-bet+ and FoxP3+T-bet+ TILs from all CD3+ TILs as well as from all CD4+ TILs 
translated	into	significantly	shorter	OS	of	T-DLBCL	patients.	The	proportion	of	FoxP3-T-bet+ 
TILs from all CD4+	TILs	did	not	have	significant	association	with	survival.	M.P. et al. unpublished results.
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Figure 11. The association of distinct TIL subtypes, their immunophenotypes, and PD-1+ 
cells with DSS of T-DLBCL patients. A forest plot with univariate analysis using continuous 
variables showing the association of higher proportion of CD3+ TILs in general, CD4+ TILs, 
CD8+ CTLs, PD-1+ CD4+ TILs as well as PD-1+ CTLs with longer DSS of T-DLBCL patients. Higher 
proportion of T-bet+ and FoxP3+T-bet+ TILs from all CD3+ TILs as well as from all CD4+ TILs 
translated	into	significantly	shorter	DSS	of	T-DLBCL	patients.	The	proportion	of	FoxP3+T-bet+ 
TILs from all CD4+	TILs	did	not	have	significant	association	with	survival.	M.P. et al. unpublished results.
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Figure 12. The association of TAMS, lymphoma cells, and PD-L1+ cells with OS of T-DLBCL 
patients. A forest plot with univariate analysis using continuous variables showing the asso-
ciation of PD-L1+ cells in general as well as PD-L1+ TAMs with longer OS of T-DLBCL patients. 
No association with survival could be seen with the proportion of PD-L1+CD68- cells. However, 
higher proportion of PD-L1+ lymphoma cells from all lymphoma cells as well as higher propor-
tion of PD-L1+ TAMs from all TAMs translated into longer OS of T-DLBCL patients. 
M.P. et al. unpublished results.
Figure 13. The association of TAMS, lymphoma cells, and PD-L1+ cells with DSS of 
T-DLBCL patients.
A	 forest	 plot	 with	 univariate	 analysis	 using	 continuous	 variables	 showing	 no	 significant	
associations of TAMs, lymphoma cells, and PD-L1+ cells with the DSS of T-DLBCL patients. 
M.P. et al. unpublished results.
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Table 12. Multivariate analysis of distinct signatures and immune cell subtypes with IPI.
Variables HRa 95% CI p-value
T-lymphocyte signature (low vs. other) 3.267 1.406-7.590 0.006
IPI (3-5) 4.436 1.945-10.117 <0.001
T-cell cluster (group A vs. group B) 0.193 0.066-0.563 0.003
IPI (3-5) 6.382 3.001-13.573 <0.001
Exhausted phenotype cluster (group C vs. group D) 0.851 0.462-1.701 0.649
IPI (3-5) 4.878 2.408-9.787 <0.001
mean CD3+ (panels 1, 2, 3, and 6) 0.967 0.943-0.991 0.007
IPI (3-5) 5.340 2.624-10.866 <0.001
mean CD3+CD4+ (panels 1, 2, 3, and 6) 0.956 0.919-0.994 0.022
IPI (3-5) 5.272 2.588-10.741 <0.001
mean CD3+CD8+ (panels 1 and 6) 0.969 0.947-0.992 0.009
IPI (3-5) 5.252 2.583-10.680 <0.001
PD-1+CD3+CD4+ 2.654 1.261-5.586 0.010
IPI (3-5) 4.907 2.275-10.585 <0.001
PD-1+CD3+CD8+ 2.259 1.075-4.748 0.031
IPI (3-5) 4.971 2.314-10.678 <0.001
T-bet+CD3+CD4+/CD3+CD4+ 1.525 1.100-2.114 0.001
IPI (3-5) 4.672 2.299-9.494 <0.001
FoxP3+T-bet+CD3+CD4+/CD3+CD4+ 4.540 2.238-9.211 <0.001
IPI (3-5) 1.533 1.077-2.181 0.018
PD-L1+CD68+ 2.214 1.054-4.650 0.036
IPI (3-5) 4.325 2.008-9.312 <0w.001
PD-L1+CD68+/CD68+ 2.275 1.054-4.909 0.036
IPI (3-5) 3.608 1.643-7.923 0.001
HRa,	Hazard	Ratio;	CI,	Confidence	Interval;	IPI,	International	Prognostic	Index.	M.P.	et	al.	unpublished	results.
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6 Discussion
PTL is a rare and aggressive lymphoma entity with a high tendency of CNS relapse and dismal 
outcome, typically presenting among elderly men and representing DLBCL histologically. Due 
to the rareness of the disease, no randomized clinical trials have been conducted in T-DLBCL, 
and the current standard of care is based on retrospective data and few prospective, phase II 
trials.	During	the	last	few	years,	chromosomal,	gene	expression	profiling,	and	immunohisto-
chemical studies have led to advancements in the understanding of lymphoma biology and 
the unique characteristics of T-DLBCL. The role of TME has been the focus of many recent lym-
phoma studies, and the impact of distinct immune cell subtypes and their immunophenotypes 
in the TME is gradually beginning to unfold. The characteristics and the impact of TME and 
the	different	tumor-infiltrating	immune	cell	phenotypes	in	T-DLBCL	have	not,	however,	been	
thoroughly studied before.
In the lack of phase III trials, the data presented in this relatively large Nordic collaborative 
study in substudy I brings important information on the outcome of T-DLBCL patients treated 
with	different	 treatment	 regimen	and	modalities.	The	findings	of	 translational	 studies	 (sub-
studies II-IV) identify a novel T-lymphocyte signature which clearly separates patients with dif-
ferent outcomes and responses to immunochemotherapy as well as present novel information 
on the content, distribution, and role of TILs, TAMs, and their immunophenotypes in T-DLBCL, 
further discovering subpopulations of distinct immune cell subtypes that have association with 
the survival of T-DLBCL patients.
6.1 Clinical data and different treatment modalities
T-DLBCL is known to present with a relatively high incidence of CNS relapses, resulting in 
poor patient survival [17,85]. Previous literature and clinical practice guidelines therefore rec-
ommend the use of CNS prophylaxis as part of the treatment in T-DLBCL [15,85,97,484]. In 
the lack of phase III trials, the optimal administration of CNS prophylaxis has not, however, 
been	univocally	defined,	and	especially	the	role	of	IT	CNS-targeted	chemotherapy	has	been	
controversial. Some retrospective series from the pre-rituximab era have reported improved 
PFS rates among patients treated with IT CNS-targeted chemotherapy but have not been able 
to	further	specify	the	beneficial	role	of	IT	administered	chemotherapy	[15,85].	Due	to	lack	of	
evidence, at least in the Nordic countries, the use of IT CNS-targeted chemotherapy is not 
very common, and the data provided by our study gives more backbone to the decision of not 
including it in the treatment regimen of T-DLBCL patients [485].
The	benefit	of	IV	CNS-targeted	chemotherapy	in	T-DLBCL	has	not	been	thoroughly	stud-
ied. Although one of the conducted phase II trials included IT CNS-targeted chemotherapy as 
part of the treatment regimen and the other phase II trial included IV CNS-targeted chemo-
therapy, the results of these two independent studies cannot be compared and no assump-
tions	can	be	drawn	on	the	benefit	of	either	treatment	approach	[15,16].	Considering	the	over-
all lack of evidence on the optimal administration of CNS-targeted chemotherapy in T-DLBCL, 
the	results	of	our	retrospective	analysis	showing	significantly	 improved	patient	survival	with	
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the addition of IV CNS-targeted chemotherapy seem particularly important. Additionally, our 
findings	highlight	the	essential	role	of	IV	CNS-targeted	chemotherapy	in	gaining	better	sys-
temic control of T-DLBCL, in addition to the aim of reducing the risk of CNS relapse. Notable is 
also	the	finding	that	despite	the	commonly	feared	toxicity	of	IV	CNS-targeted	chemotherapy	
in elderly patients, this treatment modality translated into longer survival particularly among 
patients with advanced age at diagnosis.
The effect of rituximab on the survival of T-DLBCL patients and the risk of CNS relapse in 
T-DLBCL has not been proven and seems to be controversial [16,67,102,486-489]. However, 
rituximab is commonly included in the treatment regimen of T-DLBCL and the data from our 
study supports this policy, especially among high-risk patients. Treatment of the contralateral 
testis is already commonly considered crucial in the treatment of T-DLBCL patients and the 
findings	in	our	study	highly	support	this	approach	[15,101,490].	As	a	conclusion	and	based	on	
our	findings,	the	currently	recognized	standard	of	care	with	orchiectomy	followed	by	anthra-
cycline-based immunochemotherapy, IV CNS-targeted chemotherapy, and prophylactic treat-
ment of the contralateral testis can be considered, at the moment, the most recommended 
first	line	treatment	of	T-DLBCL.
6.2 Biological findings and the TME
Previous genetic studies of T-DLBCL have been more or less focused on the COO and dif-
ferent pathway activation -related factors [74,103,127,199,201]. In DLBCL, different genetic 
signatures such as immune and host response signatures, stromal signatures, and lymphoma 
driver gene signatures have been shown to separate patients into distinct subgroups with 
different genetic aberrations, phenotypes, and response to treatment [108,146,193,194,491]. 
Our aim was to characterize immune-related factors and immune cell phenotypes in T-DLBCL, 
and we found a novel T-lymphocyte signature with 121 genes enriched for T-lymphocyte mark-
ers that could clearly separate T-DLBCL patients with different survival and distinct response 
to immunochemotherapy. This T-lymphocyte signature was shown to have prognostic impact 
also in an independent cohort of primary DLBCL patients, further highlighting the importance 
of the signature genes.
We show that high expression of individual T-lymphocyte surface markers such as 
CD3D/E/G, CD4, and CD8A/B translated into favorable outcome in T-DLBCL, emphasizing 
the prognostic role of TILs in the TME of T-DLBCL. As a proof of concept, we observed that 
the expression of T-lymphocyte surface marker genes correlated well with the expression of 
the corresponding genes on the protein level, and a higher proportion of TILs associated with 
significantly	improved	outcome	of	patients	with	T-DLBCL	also	based	on	the	findings	from	our	
mIHC analysis. The favorable prognostic impact was seen with higher content of both CD4+ 
TILs and CTLs, was independent of IPI, and was especially evident among immunochemother-
apy-treate	patients.	These	findings	are	in	line	with	the	previously	reported	association	of	high	
TIL content with better survival of patients with DLBCL, but, to our knowledge, the results on 
the prognostic impact of TILs in T-DLBCL have not been demonstrated before [213,216,217].
In	line	with	previous	findings	on	the	common	loss	of	HLA genes in T-DLBCL, we observed 
only a minority of the T-DLBCL patients’ tumor tissue samples showing highly positive mem-
branous staining of HLA class I and II proteins [91,92,204,205]. The previously reported studies 
64 TESTICULAR DIFFUSE LARGE B-CELL LYMPHOMA; PROGNOSTIC CLINICAL, MOLECULAR, AND IMMUNOLOGICAL FACTORS
have, however, been conducted with fairly small numbers of T-DLBCL patients and have not 
been	able	to	report	an	association	of	these	findings	with	patient	survival.	With	a	considerably	
larger patient population, we were able to demonstrate that the low expression of HLA class 
I and II genes translated into worse prognosis and lower content of TILs among patients with 
T-DLBCL.	These	results	further	highlight	the	significant	role	of	TILs	in	the	TME	of	T-DLBCL	and	
present a possible mechanism of immune evasion caused by disturbed antigen presentation 
that might lead to impaired recruitment of TILs in T-DLBCL.
In order to further characterize the subtypes of host immune cells in the TME of T-DLBCL, 
we performed several mIHC panels with different markers to detect distinct TIL and TAM 
immunophenotypes and the expression of activation and exhaustion markers as well as check-
point molecules. Altogether, we observed great variation in the distribution of all studied host 
immune cells among the tumor tissue samples from different patients. Remarkable variation 
was also seen in the content of lymphoma cell immunophenotypes. To our knowledge, the 
findings	on	 the	host	 immune	and	 tumor	cell	 immunophenotypes	and	 the	variation	of	 their	
content	 in	T-DLBCL	TME	have	not	been	previously	 reported,	and	our	findings	bring	novel	
information on the diversity of the disease. We show that higher proportions of checkpoint 
receptor expressing PD-1+ TILs associate with longer survival of patients with T-DLBCL. On 
the	individual	marker	level,	PD-1	was	the	only	exhaustion	marker	significantly	translating	into	
better	patient	outcome,	and	the	association	with	survival	was	most	significant	with	the	pro-
portion to all cells (e.g. PD-1+CD3+CD8+) and less evident when analyzing the proportions of 
distinct TIL subtypes (e.g. PD-1+CD3+CD8+/CD3+CD8+). In DLBCL, PD-1 expression has been 
associated with better clinical outcome, but as the studies have not been able to detect the 
expression of PD-1 to a distinct cell subpopulation, and as PD-1 is known to be expressed on 
other immune cells as well, the results cannot be directly compared to ours [321,331,467].
Although none of the other studied T-cell exhaustion markers had an association with sur-
vival of T-DLBCL patients, when analyzing the studied exhaustion markers combined, a clear 
trend towards longer survival could be seen among patients with higher overall expression of 
the	exhaustion	markers.	We	assume	that	this	finding,	first	of	all,	emphasizes	the	overall	strong	
favorable prognostic impact of high TIL content more than barely describes an exhausted or 
de-functioning state of TILs. On the other hand, it seems that the expression of markers that 
have been considered to describe a state of exhaustion can, perhaps, also demonstrate a 
certain state of activity of the cell. In line with this hypothesis are the recently published data 
on PD-1+, LAG-3+, and TIM-3+ triple-positive CD8+ TILs presenting with a highly activated 
and functional phenotype and negative correlation to tumor burden in murine tumor models 
[492]. The number and activation of these triple-positive CD8+ TILs were shown to increase in 
response to anti-PD-L1 therapy [492]. In our patient material, the co-expression of LAG-3 and 
TIM-3 on CTLs did not have an effect on the outcome of T-DLBCL patients, but when co-ex-
pressed on CD4+ TILs, they were shown to have an adverse impact on survival. Previous data 
on the co-expression of LAG-3 and TIM-3 on CD4+ T-cells are scarce and have been reported 
in infections such as HIV and some solid tumors [493-496]. Recently published results on 
colorectal cancer suggest the co-expression identifying a subgroup of potent CD4+ Tregs that 
suppress the activity of macrophages in the TME [495]. Based on these results, it can be spec-
ulated whether the adverse prognostic impact of LAG-3+TIM-3+CD4+ TILs in T-DLBCL could be 
a result from Treg-mediate downregulation of TAM activity.
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Despite the overall favorable prognostic impact of a high TIL content, a subgroup of 
T-bet+	 TILs	 associated	with	 significantly	worse	 survival	 of	 T-DLBCL	patients,	 independently	
of IPI and especially among immunochemotherapy-treated patients. The overall proportions 
of T-bet+ TILs were low, and it seems that the presence of even a small number of them is 
enough to have an adverse impact on patient outcome. Interestingly, the prognostic impact 
was particularly related to the presence of FoxP3+T-bet+ double positive TILs, and the propor-
tion of FoxP3-T-bet+ TILs did not correlate with patient survival. Based on previous literature, 
FoxP3+T-bet+ double-positive TILs have been described as Tregs that are optimized for the sup-
pression of Th1 cells [243,252,256]. We assume that the adverse impact of T-bet+ TILs on the 
outcome of T-DLBCL patients is probably mainly due to the presence of these FoxP3+T-bet+ 
double-positive Th1 cell suppressive Tregs. The presence of FoxP3
+T-bet+ Tregs has also been 
recognized and associated to tumor growth in lung carcinoma but, to our knowledge, their 
proper	functional	role	in	tumors	remains	to	be	solved	[497].	Taken	together,	our	findings	indi-
cate that despite the overall favorable prognostic impact of TILs, the TME is very complex. 
The	results	suggest	that	distinct	subpopulations	of	TILs,	and	perhaps	more	specifically,	sub-
populations	of	tumor-infiltrating	Tregs, might interact with other host immune cells, leading to 
suppression of anti-tumor host immunity. 
Studying	the	expression	of	checkpoint	molecules	on	other	tumor-infiltrating	immune	cells	
and tumor cells, we observed that altogether higher expression of PD-L1 translated into sig-
nificantly	longer	survival	of	T-DLBCL	patients.	This	association	seems	to	be	especially	related	
to the expression on CD68+ TAMs, although also higher proportions of PD-L1+ lymphoma cells 
seem to be advantageous. Interestingly, the content of PD-L1 expressing CD68+ TAMs corre-
lated with the content of PD-1 expressing TILs. Taking into account previous reports on PD-L1 
expression on tumor cells associating with immune escape and T-cell non-responsiveness, as 
well as promising preliminary results with PD-1 blockade therapy in T-DLBCL, our results seem 
somewhat paradoxical [209,288,476]. The PD-1–PD-L1 pathways have, however, been shown 
to be much more complicated, and besides PD-1, also additional binding sites to PD-L1 and 
PD-L2 have been reported [498-500]. Furthermore, PD-1 expression by TAMs has been shown 
to inhibit phagocytosis and tumor immunity, and blockade of the PD-1–PD-L1 pathway seems 
to reverse these impacts [443]. Altogether, our results highlight the diverse and possibly clin-
ically relevant PD-1–PD-L1 signaling and interactions between TAMs and TILs. Since the sig-
nificant	association	with	survival	was	seen	only	with	higher	proportions	of	PD-L1+ CD68+ TAMs 
and not with the content of any other, M2-like, TAM phenotypes, it can be speculated whether 
the favorable prognostic impact of PD-L1+ TAMs in T-DLBCL might be due to the presence of 
a subpopulation of M1-like PD-L1+ TAMs. At least it can be assumed that the association with 
survival is not restricted to M2-like phenotype PD-L1+	TAMs	alone.	These	findings	are	in	line	
with the previously reported association of CD68+ TAMs with longer survival of patients with 
DLBCL and bring novel information on the role of TAMs in T-DLBCL since, to our knowledge, 
no	previous	 reports	on	 the	possible	prognostic	 influence	of	TAMs	have	been	published	 in	
T-DLBCL [220,221].
In	our	patient	material,	the	overall	beneficial	role	of	TILs	and	PD-L1+ TAMs was especially 
evident among immunochemotherapy-treated T-DLBCL patients and can therefore relate to 
the crucial role of host immunity and the pre-existing TIL and TAM populations that can induce 
response to both chemotherapy agents and rituximab. The hypothesis is supported by previ-
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ous	findings	on	cyclophosphamide-	and	doxorubicin-induced	anti-tumor	immune	response,	
macrophage-involved Ab-dependent cell-mediated cytotoxicity, as well as CD4+ T-cell- and 
CTL-dependent “vaccinal effect” of rituximab and alterations in the peripheral blood T-cell 
status upon immunochemotherapy [447-450,453,454,501,502]. Additionally, as HLA proteins 
are needed in proper antigen presentation and tumor cell recognition, loss of HLA protein 
expression may, in addition to facilitating lymphoma cells to escape from immunosurveillance, 
also lead to impaired recruitment of TILs and inadequate response to therapeutic agents 
[227,230].
6.3 Strengths and limitations
Even though this is one of the largest clinical cohorts reported in T-DLBCL, the number of 
patients in this study is still relatively low, which should be taken into account when inter-
preting the results of this study. Limitations of the Nordic collaborative study also include 
the retrospective analysis of the data and the potential patient selection bias caused by this 
approach. Due to the retrospective nature of the study, the patient material and their treat-
ments	are	heterogeneous.	The	findings	on	the	benefit	of	different	treatment	modalities	need	
to be interpreted with caution since the relapse rate might be underestimated among the 
most fragile patients not necessarily actively diagnosed with a potential lymphoma relapse. 
Additionally, patients with the most comorbidities were most likely not treated with the most 
intense	treatment	modalities,	possibly	further	impairing	the	results	on	the	efficacy	of	the	less	
toxic treatment approaches. As the overall incidence of CNS relapses was low in our patient 
material, evaluation of the possible effect of different treatment modalities on the risk of CNS 
relapse is very challenging.
The advantages of the biological studies presented in this thesis include the considera-
bly high number of T-DLBCL patients with primary diagnostic tumor tissue available for the 
analysis compared to the previously published biological data on T-DLBCL. In addition, the 
mIHC technology used in this study provided us the opportunity of characterizing distinct 
immune cell subtypes, their immunophenotypes, and the localization of immune checkpoint 
and	exhaustion	markers	more	specifically	than	traditional	IHC.	The	restrictions	include	the	lack	
of functional analysis of different immune cell phenotypes and their interactions in the TME as 
well as limitations caused by the rareness of this malignancy. The number of patients treated 
with current standard of care including immunochemotherapy is inevitably low in the biolog-
ical	studies	of	this	thesis,	not	necessarily	enabling	us	to	detect	all	significant	associations	of	
distinct immune cell subtypes and their immunophenotypes with clinical factors and patient 
outcome. Additionally, our data provides information on the TME of T-DLBCL at the time of 
diagnosis but leaves out the knowledge on possible changes in the contribution and role of 
the immune cells during lymphoma treatments.
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6.4 Future perspectives
With the limitations related to the rareness of T-DLBCL, the possibility of evaluating different 
treatment modalities in a randomized phase III trial are limited, and the currently recognized 
standard	of	 care	 seems	 justified	based	on	 several	 retrospective	 analyses	 and	 few	phase	 II	
trials. The results from our Nordic collaborative study support the current treatment policy 
and highlight the importance of IV CNS-targeted chemotherapy. Future perspectives con-
cerning clinical studies should, however, evaluate possible less toxic treatment modalities for 
the elderly more fragile patients not eligible for the current standard of care with an intense 
chemotherapy approach.
The	findings	of	our	biological	studies	give	significant	novel	 information	on	the	genetic	
landscape	as	well	as	tumor-infiltrating	immune	cell	subtypes,	their	immunophenotypes,	dis-
tribution, and correlation to known clinical and biological risk factors and survival in T-DLBCL. 
Within the last years, the therapeutic landscape of both solid tumors and lymphomas has dra-
matically changed with the introduction of several new targeted therapies, including check-
point inhibitors targeting the PD-1–PD-L1 pathway [472,503]. Based on preliminary results, the 
PD-1 Ab nivolumab seems promising also in T-DLBCL, and further studies are ongoing [476]. 
Abs	targeting	inhibitory	receptors	TIM-3	and	LAG-3	have	also	been	studied,	and	the	findings	
suggest that the function of these receptors is reversible [251,339,348,496,504]. Based on 
data provided by our studies, future clinical trials should include patients with T-DLBCL in 
studies evaluating the effectiveness of these Abs. Furthermore, as mAbs are commonly much 
more well tolerated than chemotherapy, this might be one solution for providing effective per-
sonalized medicine treatment approaches also for elderly, more fragile patients in the future.
Future perspectives on biological studies should focus on further characterizing the func-
tional role of distinct immune cell subtypes in the TME of T-DLBCL. Studying cell-to-cell inter-
actions between Tregs and other host immune cells such as TAMs and Th1 cells would be one 
interesting approach. The impact of treatments, especially immune checkpoint inhibitors, on 
the contribution and role of immune cells in the TME would bring important new information, 
and would require repetitive tumor biopsies also after and in between the treatments. Inter-
actions between tumor cells and the host immune cells might also be different in T-DLBCL 
compared to other, primary DLBCLs presenting at sites that are not immune-privileged. As 
PCNSL is known to share several biological features with T-DLBCL and as the CNS relapse rate 
of	T-DLBCL	is	known	to	be	significantly	high,	another	interesting	aspect	in	the	future	would	
be to study the genetic landscape and the possible interactions between tumor cells and 
different host immune cells in tissue samples of T-DLBCL patients’ CNS relapses and relapses 
outside	of	the	CNS	and	the	contralateral	testis.	Comparing	the	results	with	findings	in	PCNSL	
could perhaps further widen our understanding of these rare and unique lymphoma subtypes 
presenting at immune-privileged sites. 
68 TESTICULAR DIFFUSE LARGE B-CELL LYMPHOMA; PROGNOSTIC CLINICAL, MOLECULAR, AND IMMUNOLOGICAL FACTORS
7 Summary
T-DLBCL is a rare and aggressive lymphoid malignancy with dismal prognosis and a high 
recurrence rate. Due to the lack of prospective randomized clinical trials the evidence on dif-
ferent	treatment	modalities	has	been	frail.	The	role	of	the	TME,	more	specifically	TAMs,	TILs,	
and T-cell exhaustion, has been uncharacterized. The aim of this study was to evaluate the 
treatment results of T-DLBCL patients and to characterize the role and prognostic value of the 
TME in T-DLBCL.
1. The results of this thesis support the use of the currently recognized standard of care with 
anthracycline-based immunochemotherapy combined with IV CNS-targeted chemother-
apy	 and	 prophylactic	 treatment	 of	 the	 contralateral	 testis	 as	 the	 first	 line	 treatment	 of	 
T-DLBCL patients.
2.	 T-cell	inflamed	TME	associates	with	favorable	survival	in	T-DLBCL.
3. The content of different TIL immunophenotypes varies between T-DLBCL patients. Higher 
content of TILs expressing PD-1 associates with longer survival, while subpopulations of 
Tregs predict worse outcome of patients with T-DLBCL.
4. High content of PD-1+ TILs correlates with the proportions of PD-L1+ TAMs and translates 
into longer survival of patients with T-DLBCL.
Future	studies	are	needed	to	further	characterize	the	functional	roles	of	distinct	tumor-infiltrat-
ing immune cells in T-DLBCL, and to evaluate novel and targeted therapeutic options also for 
elderly, more fragile patients with T-DLBCL.
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